



IN THE DISTRICT COURT OF CLEVELAND COUNTY  
STATE OF OKLAHOMA

Document split into multiple parts

**PART G**

STATE OF OKLAHOMA, ex rel., )  
MIKE HUNTER, )  
ATTORNEY GENERAL OF OKLAHOMA, )

Plaintiff, )

vs. )

Case No. CJ-2017-816  
Judge Thad Balkman

- (1) PURDUE PHARMA L.P.; )
- (2) PURDUE PHARMA, INC.; )
- (3) THE PURDUE FREDERICK COMPANY; )
- (4) TEVA PHARMACEUTICALS USA, INC.; )
- (5) CEPHALON, INC.; )
- (6) JOHNSON & JOHNSON; )
- (7) JANSSEN PHARMACEUTICALS, INC; )
- (8) ORTHO-MCNEIL-JANSSEN )  
PHARMACEUTICALS, INC., n/k/a )  
JANSSEN PHARMACEUTICALS; )
- (9) JANSSEN PHARMACEUTICA, INC., )  
n/k/a JANSSEN PHARMACEUTICALS, INC.; )
- (10) ALLERGAN, PLC, f/k/a ACTAVIS PLC, )  
f/k/a ACTAVIS, INC., f/k/a WATSON )  
PHARMACEUTICALS, INC.; )
- (11) WATSON LABORATORIES, INC.; )
- (12) ACTAVIS LLC; and )
- (13) ACTAVIS PHARMA, INC., )  
f/k/a WATSON PHARMA, INC., )

Defendants. )

STATE OF OKLAHOMA } S.S.  
CLEVELAND COUNTY }

**FILED**

MAY 23 2019

In the office of the  
Court Clerk MARILYN WILLIAMS

**PRETRIAL CONFERENCE ORDER**

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1344	05/05/2011	[Email] Meeting invite to review outstanding question on Nucynta ER savings card	JAN-MS-05435624			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1345	5/23/2011	Duragesic Tenth Risk Management Plan Progress Report	JAN-MS-00185384	JAN-MS-00185384		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1346	6/8/2011	DUR meeting recording and transcription	OUCOP-00038936			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1347	06/08/2011	[Email] Re: request for Nucynta precautions/safety issues presentation	JAN-MS-00241364			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1348	6/9/2011	Nucynta IR PADER Feb 2011-May 2011	JAN-MS-00235242	JAN-MS-00235242		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1349	6/10/2011	NAVIPPRO Surveillance Report Q1 2011 (1/1/2011-3/31/2011)	JAN-OK-00009242	JAN-OK-00009299		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1350	6/10/2011	NAVIPPRO Surveillance Report Q4 2011 (10/1/2010-12/31/2010)	JAN-OK-00008957	JAN-OK-00009002		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1351	6/15/2011	Duragesic PSUR May 2010-Apr 2011	JAN-MS-00185387	JAN-MS-00198440		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1352	7/5/2011	RADARS Fentanyl Data Q1 2011	JAN-MS-01545296	JAN-MS-01545597		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1353	07/05/2011	2011 Let's Talk Pain Partner Fees	JAN-MS-00835556	JAN-MS-00835557		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1354	7/8/2011	RADARS System Tapentadol Report Q1 2011	JAN-OK-00044609	JAN-OK-00044919		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1355	07/11/2011	Boscarino, Joseph A. - "Prevalence of Prescription Opioid-use Disorder Among Chronic Pain Patients: Comparison of the DSM-5 vs. DSM-4 Diagnostic Criteria"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1356	7/13/2011	Draft Prescribe Responsibly Press Release	JAN-MS-00939635	JAN-MS-00939635		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1357	07/15/2011	FW: FOR FINAL REVIEW: Smart Moves Toolkit and supporting Web pages	JAN-MS-00835577	JAN-MS-00835578		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1358	07/19/2011	[Email] Meeting invite regarding Nucynta 2011 budget discussion.	JAN-MS-00246670	JAN-MS-00246670		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1359	07/21/2011	[Email] For Review: NUCYNTA ER Press Materials	JAN-MS-02278334	JAN-MS-02278336		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1360	08/03/2011	FW: Prescribe Responsibly Website 02UNB11027	JAN-MS-00255873	JAN-MS-00255874		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1361	8/3/2011	JOM Standard Operating Procedure: License Management	JAN-MS-03124088	JAN-MS-03124100		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1362	8/5/2011	[Email] NUCYNTA ER- MRC Review- SCG Training Workshop	JAN-MS-00319588	JAN-MS-00319588		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1363	08/10/2011	DURB Meeting Packet, Aug. 10, 2011	OKAG-00014174	OKAG-00014274		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1364	8/11/2011	Nucynta and Nucynta ER REMS Webpage Links	JAN-MS-01047105	JAN-MS-01047106		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1365	8/11/2011	[Email] WICO - NUCYNTA ER Websites	JAN-MS-01047103	JAN-MS-01047104		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1366	08/17/2011	Email from T. Hillmer to group re REMS, FDA comments/revised documents	JAN-MS-01047546	JAN-MS-01047547		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1367	8/19/2011	Email from S. Nicholson to group re Opioid REMS Submissions	JAN-MS-00454121	JAN-MS-00454122		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1368	08/23/2011	[Email] PLEASE READ: Important Launch Details	JAN-MS-00836143	JAN-MS-00836144		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1369	8/25/2011	Nucynta ER Risk Evaluation and Mitigation Strategy (REMS)	JAN-MS-01489228	JAN-MS-01489275		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1370	08/25/2011	Nucynta ER REMS	JAN-MS-03088737	JAN-MS-03088784		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1371	9/2/2011	NAVIPPRO Surveillance Report Q2 2011 (4/1/2011-6/30/2011)	JAN-OK-00009050	JAN-OK-00009107		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1372	9/6/2011	Korff M., et al., Long-Term Opioid Therapy Reconsidered, Annals of Internal Medicine, Volume 155, No. 5, pp.327-329, September 5, 2011				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1373	9/12/2011	Nucynta IR PADER May 2011-Aug 2011	JAN-MS-00235245	JAN-MS-00235245		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1374	9/14/2011	Key Characteristics of NAVIPPRO, RADARS, SKIP, and RADARS OTP Surveillance Systems	JAN-MS-02267890	JAN-MS-02267898		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1375	9/14/2011	DURB Meeting Packet	OKAG-00014432	OKAG-00014500		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1376	9/15/2011	Email from M. Kim re Metrics Background document for IWG F2F Meeting September 19, 2011 attaching summary re RADARS and NAVIPPRO	JAN-MS-02267889	JAN-MS-02267889		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1377	09/28/2011	[Word] Nucynta ER Frequently Asked Questions	JAN-MS-02266302	JAN-MS-02266324		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1378	10/5/2011	RADARS System Fentanyl Data Q2 2011	JAN-MS-01551506	JAN-MS-01551800		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1379	10/5/2011	RADARS System Tapentadol Report Q2 2011	JAN-OK-00044920	JAN-OK-00045190		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1380	10/07/2011	[Report/Memo] Continuing Education, Grant Proposal - Overcoming Disparities in Pain Management: Beyond the Decade of Pain	JAN-MS-00403401	JAN-MS-00403401		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1381	10/10/2011	[Email] MRC Review-NUCYNTA ER FAQs	JAN-MS-02266298	JAN-MS-02266301		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1382	10/28/2011	Johnson & Johnson sNDA for Nucynta ER diabetic neuropathy	JAN-MS-01046321	JAN-MS-01046322		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1383	11/22/2011	Nucynta ER Opioid Dose Conversion Web Advisory Board	JAN-MS-02827954	JAN-MS-02827986		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1384	11/23/2011	[Email] Nucynta Performance Dashboard	JAN-MS-00775681	JAN-MS-00775682		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1385	11/23/2011	[Email] Nucynta ER Fourth Quarter Tracking	JAN-MS-00346687	JAN-MS-00346688		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1386	12/01/2011	[Doc] Exhibit B - Work Order	JAN-MS-00828369	JAN-MS-00828375		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1387	12/2/2011	Duragesic Eleventh Risk Management Plan Progress Report	JAN-MS-00291163	JAN-MS-00291163		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1388	12/6/2011	NAVIPPRO Surveillance Report Q3 2011 (7/1/2011-9/30/2011)	JAN-OK-00009108	JAN-OK-00009173		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1389	12/12/2011	Nucynta IR PADER Aug 2011-Nov 2011	JAN-MS-00235252	JAN-MS-00235252		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1390	12/12/2011	[Doc] Exhibit B - Work Order	JAN-MS-00828376	JAN-MS-00828382		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1391	12/12/2011	[Doc] Exhibit B - Work Order	JAN-MS-00828398	JAN-MS-00828404		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1392	12/13/2011	Nucynta ER PADER Aug 2011-Nov 2011	JAN-MS-00228332	JAN-MS-00228332		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1393	12/14/2011	DURB Meeting Packet, Dec. 14, 2011	OKAG-00015124	OKAG-00015182		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1394	12/15/2011	Nucynta Oral Solution NDA Cover Letter	JAN-MS-00230206	JAN-MS-00230206		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1395	12/15/2011	Nucynta Oral Solution Application to Market a New Drug	JAN-MS-00230193	JAN-MS-00230193		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1396	01/05/2012	[Email] CE Pain Announcement: "Role and Clinical Insights of Pharmacotherapy in Chronic Pain Management"	JAN-MS-00403818	JAN-MS-00403820		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1397	1/9/2012	RADARS System Tapentadol Report Q3 2011	JAN-OK-00045191	JAN-OK-00045381		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1398	1/9/2012	Email from DocAlert to M. McIntire re: Requested DocAlert(R): Dosing and Titration Information Available for Extended-Release Opioid Analgesic				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1399	1/9/2012	[Nucynta ER] Doc Alert Dosing Email	JAN-MS-01090372	JAN-MS-01090379		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1400	01/09/2012	Email from DocAlert to M. McIntire re: Requested DocAlert(R): Dosing and Titration Information Available for Extended-Release Opioid Analgesic (Jan. 9, 2012)	JAN-MS-01090372	JAN-MS-01090379		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1401	01/10/2012	[Email] Pain CME Announcement - "The Pain Medical Home: A Call for Transformation in Chronic Pain Care"	JAN-MS-00403823	JAN-MS-00403825		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1402	01/11/2012	[Email] Pain CME Announcement - Pharmacist's Roadmap to Pain Management: New Directions to Improved Patient Care	JAN-MS-00403821	JAN-MS-00403822		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1403	1/19/2012	Nucynta (Tapentadol Hydrochloride) Immediate Release: Fourth Safety Surveillance Plan Progress Report	JAN-MS-00235278	JAN-MS-00235278		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1404	01/31/2012	[Email] Literature Searches / PDF of Articles for Veterans and Chronic Pain	JAN-MS-02293087	JAN-MS-02293089		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS [Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them]
J1405	02/03/2012	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use, Nucynta ER	JAN-MS-00228657	JAN-MS-00228657		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1406	02/08/2012	DURB Meeting Packet, Feb. 8, 2012	OKAG-0000253	OKAG-0000304		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1407	02/08/2012	DUR's meeting packet	OKAG-0000253	OKAG-0000304		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1408	02/09/2012	Nominations for Institutional Nucynta Speaker Training	JAN-MS-00253054	JAN-MS-00253055		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1409	3/7/2012	NAVIPPRO Surveillance Report Q4 2011 (10/1/2011-12/31/2011)	JAN-OK-00009174	JAN-OK-00009241		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1410	3/8/2012	DUR meeting minutes re vote to PA Nucynta ER, Memo from Univ. of Oklahoma to DUR re: Packet Contents for Board Meeting - March 14, 2012				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1411	03/13/2012	Karen H.Seal, MD, et al., Association of mental health disorders with prescription opioids and high-risk opioid use in veterans of Iraq and Afghanistan, Journal of American Medical Association, Vol. 307, No. 9, pp. 940-947, March 13, 2012				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1412	3/14/2012	DUR meeting recording and transcription	OUCOP-00038913			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1413	3/14/2012	DUR meeting packet; PA Nucynta ER	OKAG-00013516			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1414	03/14/2012	DURB Meeting Packet, Mar. 14, 2012	OKAG-00013516	OKAG-00013554		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1415	3/15/2012	Nucynta ER PADER Nov 2011-Feb 2012	JAN-MS-00228427	JAN-MS-00228427		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1416	03/19/2012	[Email] Nucynta ER Research	JAN-MS-02287901	JAN-MS-02287901		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1417	3/26/2012	Email discussing re-review of SMSC and altering the audience	JAN-MS-00940779	JAN-MS-00940781		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1418	4/4/2012	RADARS System Tapentadol Report Q4 2011	JAN-OK-00045382	JAN-OK-00045573		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS [Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them]
J1419	4/11/2012	DUR meeting packet; FY 2011 Annual Review	OKAG-00013637			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1420	04/11/2012	DURB Meeting Packet, Apr. 11, 2012	OKAG-00013637	OKAG-00013714		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1421	04/11/2012	DUR meeting packet w/FY11 Annual Review - hydrocodone most reimbursed of medications				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1422	04/24/2012	Agreement for Revision to Statement of Work	JAN-MS-00868265	JAN-MS-00868267		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1423	4/25/2012	ASTHO Multi State Invitational Team Meeting	PPLPC019000825252			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1424	4/27/2012	[Doc] Transaction Details & Product	JAN-MS-00793861	JAN-MS-00793879		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1425	5/4/2012	B. Colligen Email to R. Kohn and M. Monaghan re programs on Rx drug abuse-Follow up	JAN-MS-00916797	JAN-MS-00916798		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1426	05/04/2012	FW: NUCYNTA PR Mar-Dec SOW	JAN-MS-00868261	JAN-MS-00868262		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1427	05/04/2012	Email from Bruce Colligen to Robyn Kohn	JAN-MS-00916797	JAN-MS-00916798		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1428	5/7/2012	Dr. Li Handout	JAN-MS-01078132	JAN-MS-01078133		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1429	5/8/2012	Summary of payments made 1997-2012, in response to Senate Finance Committee request	JAN-MS-00000001	JAN-MS-00000010		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1430	05/16/2012	Email from Maryann Gribbin to David Johnson, Liam Keary, Bruce Keele, et al.	JAN-MS-05433721	JAN-MS-05433722		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1431	05/17/2012	Email from Maryann Gribbin to Maryann Gribbin, David Johnson, Liam Keary, et al.	JAN-MS-05433723	JAN-MS-05433725		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1432	05/18/2012	Email from Maryann Gribbin to Maryann Gribbin, David Johnson, Liam Keary, et al.	JAN-MS-05433726	JAN-MS-05433727		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1433	05/21/2012	Email from Maryann Gribbin to Maryann Gribbin, David Johnson, Liam Keary, et al.	JAN-MS-05433728	JAN-MS-05433729		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1434	6/1/2012	Duragesic Twelfth Risk Management Plan Progress Report	JAN-MS-00198521	JAN-MS-00198521		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1435	06/01/2012	PRC Comments on Nucynta ER Patient Brochure	JAN-MS-00772441	JAN-MS-00772452		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1436	06/01/2012	[Email] IM News	JAN-MS-02355236	JAN-MS-02355240		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1437	06/01/2012	Copy Review Approval Form for Nucynta ER Patient Brochure	JAN-MS-04145965	JAN-MS-04145965		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1438	06/01/2012	Copy Review Submission Package - Nucynta ER Patient Brochure	JAN-MS-04145969	JAN-MS-04145969		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1439	06/01/2012	Review Item # Request Form - Nucynta ER Patient Brochure	JAN-MS-04145970	JAN-MS-04145970		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1440	6/1/2012	Stefanie Emmanuel et al., Document entitled, "DURAGESIC: Twelfth Risk Management Plan Progress Report," Global Medical Safety Janssen Research & Development, LLC, 06/01/2012	JAN-MS-00198521			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1441	6/8/2012	FSMB Senate Finance Committee Letter Response	OKAG-00020937	OKAG-00020964		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1442	6/11/2012	Proposal for Interim Study Proposal	OSDH-00496328			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1443	06/11/2012	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use, Nucynta IR	JAN-MS-00230154			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1444	06/13/2012	Agreement for Revision to Statement of Work	JAN-MS-00868299	JAN-MS-00868300		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1445	6/15/2012	Nucynta ER PADER Feb 2012-May 2012	JAN-MS-00228450	JAN-MS-00228450		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1446	06/15/2012	High Level Overview of Suspicious Order Monitoring	JAN-MS-00454958	JAN-MS-00454958		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1447	6/18/2012	Duragesic PSUR May 2011-Apr 2012	JAN-MS-00198542	JAN-MS-00207023		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1448	6/19/2012	Janssen letter to FDA regarding last Duragesic Progress Report	JAN-MS-00700680	JAN-MS-00700681		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	



TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1449	06/19/2012	Letter from Mary Mulligan to Bob A. Rappaport, M.D.	JAN-MS-00700680	JAN-MS-00700681		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1450	06/21/2012	PRC Meeting Agenda	JAN-MS-03966966	JAN-MS-03966966		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1451	6/26/2012	[Email] Is it possible to have slide deck tomorrow by noon? I want to review it with some team members and next week they are on vacation	JAN-MS-00341645	JAN-MS-00341646		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1452	7/3/2012	NAVIPPRO Surveillance Report P1 2012 (1/1/2012-4/30/2012)	JAN-OK-00009535	JAN-OK-00009624		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1453	7/9/2012	RADARS System Tapentadol Report Q1 2012	JAN-OK-00045774	JAN-OK-00045966		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1454	07/09/2012	FW: Updated Nucynta PR SOW Agreement Letter	JAN-MS-00868297	JAN-MS-00868298		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1455	07/11/2012	DURB Meeting Packet, Jul. 11, 2012	OKAG-00014108	OKAG-00014173		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1456	07/11/2012	DUR meeting packet, PA Subsys				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1457	07/13/2012	[Email] Confidential Communications re Nucynta forecast	JAN-MS-00775819	JAN-MS-00775820		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1458	7/16/2012	[Email] PRI - Nucynta Pain Management Newsletter	JAN-MS-01094764	JAN-MS-01094764		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1459	07/23/2012	Totality Request ID: 128665	JAN-MS-00926528	JAN-MS-00926538		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1460	7/25/2012	PROP Petition				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1461	7/25/2012	Letter from PROP to FDA re: PROP Petition				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1462	07/26/2012	[Email] Nucynta Staffing Scenarios	JAN-MS-00775844	JAN-MS-00775844		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1463	07/28/2012	[Email] 2H Nucynta sales.	JAN-MS-00303382	JAN-MS-00303382		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1464	7/30/2012	Nucynta (Tapentadol) Extended-Release: First Safety Surveillance Plan Progress Report	JAN-MS-00228466	JAN-MS-00228466		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1465	7/30/2012	Document entitled, "NUCYNTA Extended-Release: First Safety Surveillance Plan Progress Report," Global Medical Safety Janssen Research & Development, LLC, 07/30/2012	JAN-MS-00228466			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1466	08/02/2012	[Email] Nucynta ER DPN Launch Plan	JAN-MS-00775877	JAN-MS-00775878		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1467	08/08/2012	DURB Meeting Packet, Aug. 8, 2012	OKAG-00001121	OKAG-00001173		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1468	8/8/2012	Nucynta Ipad Materials	JAN-MS-00341809	JAN-MS-00341809		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1469	08/08/2012	DUR meeting packet, PA Subsys				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1470	08/08/2012	DUR meeting minutes re PA Subsys				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1471	08/08/2012	Table of Examples of Actual Medicine Take-Back Program Costs, Local Hazardous Waste Management Program in King County				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1472	08/09/2012	Email from Patricia Yap to Christopher Horn, John Haney, et al.	JAN-MS-00916719	JAN-MS-00916722		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1473	08/09/2012	Janssen Contributions Committee Meeting Notes and Documents	JAN-MS-02496824	JAN-MS-02496844		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1474	08/15/2012	Fine P., et al., American Academy of Pain Medicine Response to PROP Petition to the FDA That Seeks to Limit Pain Medications for Legitimate Noncancer Pain Sufferers, Pain Medicine, Volume 13, pp. 1259-1264, 2012				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1475	08/15/2012	Letter from M. Grabis to FDA re petition from Physicians for Responsible Opioid Prescribing	OKEXPERT-00008355			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1476	8/28/2012	FDA Approval Nucynta ER sNDA for diabetic neuropathy	JAN-MS-02285274	JAN-MS-02285359		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1477	9/12/2012	DURB Meeting Packet	OKAG-00014362	OKAG-00014431		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1478	9/12/2012	DURB Meeting Packet	OKAG-00005307	OKAG-00005499		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1479	9/18/2012	Nucynta ER PADER May 2012-Aug 2012	JAN-MS-00228469	JAN-MS-00228469		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1480	9/18/2012	Email re: Rx loophole blackhole	ODMHSAS-00048314			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1481	09/18/2012	Nucynta ER PADER Feb 2012-May 2012	JAN-MS-00228469	JAN-MS-00228469		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1482	09/21/2012	NUCYNFA ER Patient Brochure - Client Review	JAN-MS-00759762	JAN-MS-00759762		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1483	9/24/2012	Email re Board of Dentistry	OBD-00028728			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1484	09/24/2012	Ballantyne J., et al., Opioid Dependence vs Addiction - A Distinction without a Difference, Arch Intern Med, Volume 172, No. 17, September 24, 2012				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1485	10/1/2012	RADARS System Tapentadol Report Q2 2012	JAN-OK-00045967	JAN-OK-00046156		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1486	10/10/2012	Nucynta and Nucynta ER Speaker Training	JAN-MS-00027221	JAN-MS-00027347		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1487	11/7/2012	NAVIPPRO Surveillance Report P2 2012 (5/1/2012-8/31/2012)	JAN-OK-00009300	JAN-OK-00009413		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1488	11/14/2012	DURB Meeting Packet	OKAG-00014951	OKAG-00015010		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1489	11/14/2012	DUR meeting packet, report on duplication of narc therapy				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1490	11/20/2012	AAPM site/opportunity for discussion	JAN-MS-0270442	JAN-MS-0270443		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1491	11/21/2012	Email and attachment re: Ease the Pain	OBN-00137447 and OBN-00137448			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1492	12/04/2012	2012 Schedule of Home Study Test 01	JAN-MS-00337392			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1493	12/5/2012	[Email] Request for Friends of the Court	JAN-MS-00992073	JAN-MS-00992074		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1494	12/11/2012	Janssen Contract with Quintiles	JAN-MS-00576727	JAN-MS-00576746		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1495	12/11/2012	[Work Order] Fifth Change Order for Work Order #6724	JAN-MS-01971374	JAN-MS-01971393		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1496	12/12/2012	Press release - Marketing clearance for post-surgical pain candidate IONSYS expected in early 2014				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1497	12/18/2012	Nucynta ER PADER Aug 2012-Nov 2012	JAN-MS-00228497	JAN-MS-00228497		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1498	12/20/2012	Second Nucynta Safety Surveillance Plan Progress Report	JAN-MS-00228506	JAN-MS-00228506		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1499	12/20/2012	Document entitled, "NUCYNTA (Tapendol) Extended Release: Second Safety Surveillance Plan Progress Report," Global Medical Safety Janssen Research & Development, LLC, 12/20/2012	JAN-MS-00228506			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1500	1/1/2013	Steven Proctor et al., Article entitled, "Prevalence of Substance Use and Psychiatric Disorders in a Highly Select Chronic Pain Population," American Society of Addiction Medicine, Vol. 7, Number 1, Jan/Feb. 2013				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1501	1/2/2013	Nucynta IR PADER Nov 2011-Nov 2012	JAN-MS-00235281	JAN-MS-00235281		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1502	1/2/2013	RADARS System Tapentadol Report Q3 2012	JAN-OK-00046157	JAN-OK-00046353		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1503	01/08/2013	Appendix A: Home Study Training Calendar for Nucynta and Nucynta ER (for inside sales team)	JAN-MS-00668766			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1504	01/24/2013	[Email] For Martha	JAN-MS-00468984	JAN-MS-00468984		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1505	01/24/2013	JOM Customer Service New Customer Post-Application	JAN-MS-03121166	JAN-MS-03121170		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1506	01/24/2013	JOM Standard Operating Procedure: Customer Service New Customer Post Application	JAN-MS-03124141	JAN-MS-03124145		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1507	01/24/2013	JOM Standard Operating Procedure: Customer Service New Customer Pre-Application	JAN-MS-03124146	JAN-MS-03124148		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1508	01/25/2013	Statement of Andrew Kolodny before, Food and Drug Administration Center for Drug Evaluation and Research Drug Safety and Risk Management Advisory Committee				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1509	2/2013	Proctor, Steven L. - "Prevalence of Substance Use and Psychiatric Disorders in a Highly Select Chronic Pain Population"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1510	02/01/2013	United Nations Human Rights Council, Report of the Special Rapporteur on torture and other cruel, inhuman or degrading treatment or punishment, Juan E. Mendez (Feb. 1, 2013)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1511	02/06/2013	RE: Important Outstanding Items...	JAN-MS-00753246	JAN-MS-00753248		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1512	2/6/2013	Prescribe Responsibly Slide Deck.pptx	JAN-MS-00985075	JAN-MS-00985075		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1513	02/12/13	[PDF] LETTER OF AGREEMENT FOR COMMERCIAL SUPPORT GENERAL	JAN-MS-00426700	JAN-MS-00426701		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1514	2/13/2013	DUR meeting recording and transcription	OUCOP-00038902			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1515	02/13/2013	DURB Meeting Packet, Feb. 13, 2013	OKAG-00013377	OKAG-00013429		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1516	02/13/2013	DEA Conference Attendees List	JAN-MS-03124070	JAN-MS-03124070		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1517	02/13/2013	DUR meeting minutes, re ER in T1				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1518	2/25/2013	FW: End of Life Responsibility - Abuse Prevention Programs Update?	JAN-MS-02072398	JAN-MS-02072401		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1519	3/6/2013	NAVIPPRO Surveillance Report P3 2012 (9/1/2012-12/31/2012)	JAN-OK-00009414	JAN-OK-00009534		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1520	3/7/2013	Nucynta ER Patient Brochure	JAN-MS-01387186	JAN-MS-01387186		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1521	3/7/2013	Rafael Galvez et al., Article entitled, "Tapentadol Prolonged Release Versus Strong Opioids for Severe, Chronic Low Back Pain: Results of an Open-Label, Phase 3b Study," Springer Healthcare, 03/07/2013, 30(3), pp. 229-59				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1522	3/11/2013	DUR Packet for 2/11/2003	OUCOP-00040241			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1523	3/13/2013	DUR meeting recording and transcription	OUCOP-00038953			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1524	03/13/2013	DURB Meeting Packet, Mar. 13, 2013	OKAG-00013430	OKAG-00013515		Hearsay, 12 O.S. § 2802; Relevance, 12 D.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1525	3/18/2013	Nucynta ER PADER Nov 2013-Feb 2013	JAN-MS-00228509	JAN-MS-00228509		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1526	3/26/2013	Email re study of prescribers' knowledge of drug sharing	*OSDH-00498386			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1527	3/26/2013	Email from Pam Archer to Claire Nguyen et al., re new study on prescribers and doctor shopping	OSDH-00436707			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1528	3/28/2013	Email re: Overdoses and Dr. Shopper	OBN-00138864			Hearsay, 12 O.S. § 2802; Relevance, 12 D.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1529	03/28/2013	[Email] MD Concern	JAN-MS-00753974	JAN-MS-00753976		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1530	3/29/2013	[Report] Internal Medicine Pain Sales Force - 1st Quarter 2013 Call Plan	JAN-MS-01973127	JAN-MS-01973128		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1531	03/29/2013	Internal Medicine PAIN Sales Force 1st Quarter 2013 Call Plan	JAN-MS-02734358	JAN-MS-02734359		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1532	4/3/2013	RADARS System Tapentadol Report Q4 2012	JAN-OK-00046354	JAN-OK-00046554		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1533	04/08/2013	Ballentyne J., et al., Dependence is not Addiction and "Tolerance" Declares Addiction, JAMA Intern Med, Volume 173, No. 7, April 8, 2013				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1534	4/10/2013	DUR meeting recording and transcription	OUCOP-00038973			Hearsay, 12 O.S. § 2802; Relevance, 12 D.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS [Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them]
J1535	04/10/2013	DURB Meeting Packet, Apr. 10, 2013	OKAG-00013555	OKAG-00013636		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1536	04/10/2013	DUR meeting minutes re intervention strategies for reduction of narc overprescribing				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1537	4/13/2013	RADARS System Tapentadol Report 2012 Annual	JAN-MS-02061476	JAN-MS-02061676		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1538	4/26/2013	Third Nucynta Safety Surveillance Plan Progress Report	JAN-MS-00228517	JAN-MS-00228517		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1539	4/26/2013	Document entitled, "NUCYNTA Extended-Release: Third Safety Surveillance Plan Progress Report," Global Medical Safety Janssen Research & Development, LLC, 04/26/2013	JAN-MS-00228517			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1540	6/2/2013	Nucynta ER Abuse Deterrent Labeling Change	JAN-MS-02051874	JAN-MS-02051874		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1541	6/3/2013	Type C Meeting to Discuss: Nucynta ER Abuse Deterrent Labeling Change	JAN-MS-02051874	JAN-MS-02051874		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1542	06/06/2013	Email from Christendoza Le to Nancy Nesser	OHCA-00152507	OHCA-00152517		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1543	06/06/2013	Drug Utilization Review Board Presentation Presentation, Oklahoma Health Care Authority	OKAG-00012966	OKAG-00013075		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1544	06/10/2013	Re: Nucynta ER patient brochure	JAN-MS-00754655	JAN-MS-00754656		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1545	06/11/2013	DURB Meeting Packet, Jun. 11, 2013	OKAG-00012966	OKAG-00013075		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1546	6/12/2013	DUR meeting recording and transcription	OUCOP-00038970			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1547	06/12/2013	DUR meeting packet re duplication of narc therapy				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1548	6/17/2013	Nucynta ER PADER Feb 2013-May 2013	JAN-MS-00228521	JAN-MS-00228521		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS [Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them]
J1549	6/21/2013	Duragesic PBRER/PSUR May 2012-Apr 2013	JAN-MS-00207095	JAN-MS-00213411		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1550	6/25/2013	Email from Nguyen to Doran-Redus				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1551	07/01/2013	2013-2014 Corporate Membership: Totality Request ID: 160671	JAN-MS-02525626	JAN-MS-02525631		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1552	07/01/2013	Email from Ron Kuntz to Michelle Dempsey	JAN-MS-04201134	JAN-MS-04201134		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1553	07/02/2013	Email from Michael Levitt to DEA	JAN-MS-04201132	JAN-MS-04201133		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1554	7/10/2013	DUR meeting recording and transcription	OUCOP-00038969			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1555	07/10/2013	DURB Meeting Packet, Jul. 10, 2013	OKAG-00014022	OKAG-00014107		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1556	07/10/2013	DUR meeting minutes, opioid prescribing initiative for appropriate treatment				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1557	07/19/2013	DEA Manufacturers, Importers, Exports Conference agenda, topics, and roster	JAN-MS-03124066	JAN-MS-03124069		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1558	7/22/2013	Email re Advocacy Plan	JAN-MS-00353873	JAN-MS-00353873		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1559	07/24/2013	JOM Standard Operating Procedure: Customer Service Suspicious or Excessive Orders	JAN-MS-03124101	JAN-MS-03124110		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1560	7/25/2013	NAVIPPRO Surveillance Report P1 2013 (1/1/2013-4/30/2013)	JAN-OK-00009625	JAN-OK-00009746		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1561	7/25/2013	NUCYNTA ER Pharmacy Campaign.pptx	JAN-MS-00982828			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1562	07/27/2013	[Email] NUCYNTA Speaker Bureau - Revised honorarium rates effective August 1	JAN-MS-00426174	JAN-MS-00426174		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1563	07/30/2013	Email from Martha Wick to Maryann Gribbin, JOM QA Team, Liz Allison, et al.	JAN-MS-03123994	JAN-MS-03123996		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	



TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1564	07/30/2013	Email from DEA Conference Registration to Michele Dempsey	JAN-MS-03124064	JAN-MS-03124065		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1565	08/01/2013	Email from ValueTrak Report Administrator to Shweta Raval	JAN-MS-05332010	JAN-MS-05332010		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1566	8/2/2013	Email re Rx Painkiller Counterfeits	ODMHSAS-00047184			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1567	8/13/2013	RADARS System Tapentadol Report Q1 2013	JAN-MS-01529805	JAN-MS-01530005		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1568	08/13/2013	International Drug Control Policy: Background and U.S. Responses, Liana Sun Wyler, August 13, 2013.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1569	08/14/2013	DURB Meeting Packet, Aug. 14, 2013	OKAG-00014275	OKAG-00014361		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1570	9/6/2013	Email: Why OHCA needs broader access to PMP data	OHCA-00133759			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1571	9/10/2013	FDA Response to PROP Petition				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1572	9/10/2013	Letter from J. Woodcock, Director, Ctr. for Drug Evaluation & Research, FDA, to A. Kolodny, President, Physicians for Responsible Opioid Prescribing				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1573	9/10/2013	Letter from FDA to Dr. Kolodny re: Letter from PROP to FDA re: PROP Petition				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1574	9/10/2013	Letter from FDA to Andrew Kolodny re: Response to PROP Petition re: PROP Petition				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1575	09/10/2013	Letter from FDA to Andrew Kolodny, MD				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1576	09/10/2013	Letter from J. Woodcock, Director, Ctr. for Drug Evaluation & Research, FDA, to A. Kolodny, President, Physicians for Responsible Opioid Prescribing	JAN-MS-01987735	JAN-MS-01987752		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1577	9/12/2013	Nucynta ER PADER May 2013-Aug 2013	JAN-MS-00228530	JAN-MS-00228530		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1578	10/1/2013	DURB Online Packet	OKAG-00014501	OKAG-00014545		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1579	10/02/2013	Re: Emailing: Nucynta Label and ISI Training Oct2013_MP_10_1_13	JAN-MS-00755157	JAN-MS-00755158		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1580	10/4/2013	RADARS System Tapentadol Report Q2 2013	JAN-MS-01368672	JAN-MS-01368868		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1581	10/7/2013	[Report] Nucynta ER TrainingDirect 2013 Work Order	JAN-MS-01114585	JAN-MS-01114588		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1582	10/09/2013	DUR meeting packet, FDA/DEA updates re change to Duragesic label				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1583	10/15/2013	HCV Comment Letter + Tip Sheet to Choose Health Plan	JAN-MS-04215700	JAN-MS-04215701		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1584	10/25/2013	Form 2253 - Transmittal of Advertisements and Promotional Labeling For Drugs and Biologics for Human Use	JAN-MS-03830495	JAN-MS-03830495		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1585	11/4/2013	NAVIPPRO Surveillance Report P2 2013 (5/1/2013-8/31/2013)	JAN-OK-00009747	JAN-OK-00009866		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1586	11/13/2013	DURB Meeting Packet	OKAG-00014834	OKAG-00014950		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1587	11/14/2013	Email: FW:Request for Information	OSBP-00090251			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1588	11/14/2013	Andrew Kolodny, Article entitled, "Better late than Never: Time to Up-Schedule Hydrocodone Combination Products," Pain Medicine, Vol. 14, Issue 11, 11/14/2013, pp. 1627-1628				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1589	11/15/2013	[PDF] Statement of Work Community Connect Public Health Pain Management Initiative	JAN-MS-00423093	JAN-MS-00423104		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1590	11/16/2013	Deborah Sontag, Article entitled, "Addiction Treatment with a Dark Side," New York Times, 11/16/2013				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1591	11/23/2013	JOM Standard Operating Procedure: Customer Service Customer Master Data Process	JAN-MS-05457234	JAN-MS-05457247		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1592	12/2/2013	Fourth Nucynta Safety Surveillance Plan Progress Report	JAN-MS-00228548	JAN-MS-00228548		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1593	12/03/2013	InSightCrime. Is Colombia Still a Major Heroin Producer? Marguerite Cawley. December 3, 2013.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1594	12/11/2013	DURB Meeting Packet, Dec. 11, 2013	OKAG-00015075	OKAG-00015123		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1595	12/11/2013	DUR meeting packet, report about duplication of narc therapy July - Sept 2013				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1596	12/16/2013	Engagement Letter for Janssen	JAN-MS-00984287	JAN-MS-00984295		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1597	12/18/2013	Nucynta ER PADER Aug 2013-Nov 2013	JAN-MS-00228552	JAN-MS-00228552		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1598	12/30/2013	Nucynta IR PADER Nov 2012-Nov 2013	JAN-MS-00235302	JAN-MS-00235302		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1599	12/31/2013	Oklahoma ED and UCC Opioid Prescribing Guidelines				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1600	1/2/2014	RADARS System Tapentadol Report Q3 2013	JAN-MS-01369062	JAN-MS-01369264		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1601	01/09/2014	(Proposal) Duragesic Web \$50 Coupon 2015 Program	JAN-MS-02737011	JAN-MS-02737017		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1602	1/10/2014	Email re: View Opportunity   GRANTS.GOV	OHCA-00155598			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1603	2/6/2014	Journal of Opioid Management: Evaluation of the Tamper-Resistant Properties of Tapentadol Extended-Release Tablets: Results of In Vitro Laboratory Analyses, Eric Galia et al.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1604	2/6/2014	Evaluation of the tamper-resistant properties of tapentadol extended-release tablets: Results of in vitro laboratory analyses by Eric Galia, PhD, Yinka Williams, Ben Van Hove, et al.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1605	02/12/2014	DURB Meeting Packet, Feb. 12, 2014	OKAG-00003929	OKAG-00004004		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1606	2/19/2014	Email from C. Le to N. Nesser et al. re: RE: Narcotic General Mailing	OHCA-00156627	OHCA-00156628		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1607	02/19/2014	Email from Christendoza Le to Nancy Nesser	OHCA-00156627	OHCA-00156628		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1608	2/21/2014	[Report] Work Order #6724	JAN-MS-01971394	JAN-MS-01971399		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1609	3/7/2014	NAVPPRO Surveillance Report P3 2013 (9/1/2013-12/31/2013)	JAN-OK-00009867	JAN-OK-00009988		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1610	3/10/2014	Community Connect: Mock Panel Discussion	JAN-MS-00988467	JAN-MS-00988488		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1611	3/18/2014	Nucynta ER PADER Nov 2013-Feb 2014	JAN-MS-00228556	JAN-MS-00228556		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1612	03/24/2014	NUCYNTA ER / NUCYNTA Dual dosing guide; NUCYNTA ER / NUCYNTA Dual pharmacy leave behind (intended for pharmacists); NUCYNTA ER CLBP reprint carrier; NUCYNTA ER DPN reprint carrier; NUCYNTA ESJD reprint carrier; NUCYNTA Bunioneectomy II reprint carrier; NUCYNTA Bunioneectomy I reprint carrier	JAN-MS-00577277	JAN-MS-00577277		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1613	03/25/2014	[Statement of Work] Community Connect National Program Rollout	JAN-MS-02527549	JAN-MS-02527553		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1614	03/31/2014	Smart Moves Materials_Final Review	JAN-MS-00428521	JAN-MS-00428521		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1615	4/1/2014	2015 Completed SOM Questionnaire by Anda, Inc.	JAN-MS-02966146	JAN-MS-02966146		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1616	4/4/2014	RADARS System Tapentadol Report Q4 2013	JAN-MS-01369265	JAN-MS-01369466		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1617	4/5/2014	[Email] NER Wave 7 ATU Key Insights	JAN-MS-01967614	JAN-MS-01967614		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1618	04/07/2014	EOS record of PRC approved Start Smart materials	JAN-MS-03857633	JAN-MS-03857638		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1619	4/9/2014	DUR meeting recording and transcription	OUCOP-00038958			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1620	04/09/2014	DURB Meeting Packet, Apr. 9, 2014	OKAG-00011432	OKAG-00011533		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1621	04/09/2014	Post DUR Meeting Notes	OHCA-00157152	OHCA-00157152		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1622	04/09/2014	DUR meeting packet re Retrospective DUR of Duplication of Narc Therapy - tapentadol/fentanyl not in top 25				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1623	04/15/2014	Email from Michele Dempsey to Tim Gribbin et al.	JAN-MS-00995310	JAN-MS-00995311		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1624	4/16/2014	RADARS System Tapentadol Report 2013 Annual	JAN-MS-01598871	JAN-MS-01599071		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1625	4/18/2014	Email re: Prescribers for DHCA Top 250 IR Solid Narcotic Prescribers	OHCA-00157161			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1626	4/24/2014	Statement of Medical Necessity for Ingredient Duplication Override				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1627	4/24/2014	Statement of Medical Necessity for Ingredient Duplication Override				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1628	4/24/2014	Petition for Medication Prior Authorization, Oklahoma Health Care Authority (PHARM-4)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1629	4/24/2014	Re: 4/24 Nucynta PRC Meeting Final Agenda--C1013	JAN-MS-00989212	JAN-MS-00989217		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1630	04/30/2014	Fwd: Account Removal	JAN-MS-00752983	JAN-MS-00752983		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1631	05/05/2014	[Email] Collaboration to improve Access for Patients	JAN-MS-01967941			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1632	05/09/2014	Rose J., To End Addiction Epidemic, States Focus on Stopping Doctor Shoppers, May 9, 2014				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1633	5/14/2014	DURB Meeting Packet	OKAG-00004424	OKAG-00004541		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1634	05/14/2014	DUR meeting packet, re FDA News Release about Zohydro (hydrocodone)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1635	06/11/2014	DURB Meeting Packet, Jun. 11, 2014	OKAG-00004307	OKAG-00004381		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1636	06/11/2014	DUR meeting packet, utilization breakdown of hydrocodone containing medications				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1637	06/12/2014	Hookey J., Chronic Pain and Suicide: Understanding the Association, Psychiatric Management of Pain, Volume 18, No. 435, pp.1-6, June 12, 2014				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1638	6/16/2014	Nucynta ER PADER Feb 2014-May 2014	JAN-MS-00228583	JAN-MS-00228583		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1639	06/16/2014	Suspicious Order Monitoring Due Diligence Visit Report	JAN-MS-03054664	JAN-MS-03054666		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1640	6/17/2014	Duragesic PBRER/PSUR May 2013-Apr 2014	JAN-MS-00213464	JAN-MS-00213464		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1641	06/17/2014	Janssen Benefit Risk Evaluation/Periodic Safety Update Report- Fentanyl	JAN-MS-00213464	JAN-MS-00213464		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1642	7/1/2014	RADARS System Tapentadol Report Q1 2014	JAN-MS-01368470	JAN-MS-01368671		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1643	7/1/2014	Theodore Cicero et al., Article entitled, "The Changing Face of Heroin Use in the United States - a Retrospective Analysis of the Past 50 Years," American Medical Association, Vol. 7, Number 7, 07/2014,				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1644	07/09/2014	DURB Meeting Packet, Jul. 9, 2014	OKAG-00004723	OKAG-00004813		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1645	07/09/2014	Post DUR Meeting Notes	OHCA-00003978	OHCA-00003979		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1646	7/22/2014	Email from Marhta Wick to Liz Allison, Andres Lopez, Mike Griffith, et al	JAN-MS-05433758	JAN-MS-05433760		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1647	8/1/2014	News Release	OHCA-00004297			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1648	08/04/2014	Marguerite Cawley, "Meth Trafficker Sentence Highlights Asia Ties to Mexico's Sinaloa Cartel," InSight Crime, 4 August 2014.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1649	8/13/2014	FMV Analysis.pptx	JAN-MS-01082758	JAN-MS-01082758		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS [Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them]
J1650	8/15/2014	NAVPPRO Surveillance Report P1 2014 (1/1/2014-4/30/2014)	JAN-OK-00009989	JAN-OK-00010114		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1651	08/21/2014	[Email] from Gary Vorsanger re HCP Rescheduling	JAN-MS-00577454			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1652	8/25/2014	Email from Curtis to Willhour	OCME-00090878			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1653	8/29/2014	[Memo] Appropriation Request - Project Vortex II	JAN-MS-01973590	JAN-MS-01973592		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1654	09/02/2014	EOS Project Initiation Submission	JAN-MS-03830441	JAN-MS-03830444		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1655	9/5/2014	Email re: Added a Paragraph	OHCA-00158785			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1656	9/8/2014	Nucynta and Nucynta ER Management Presentation	JAN-MS-02735018	JAN-MS-02735110		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1657	9/9/2014	PRC Meeting Agenda	JAN-MS-00997372	JAN-MS-00997372		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1658	9/10/2014	EOS Task Assignment Reminder: Review Submission Due in 1 Day	JAN-MS-01390669	JAN-MS-01390669		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1659	09/10/2014	DUR meeting minutes, re: PA Zyohydro ER, and reviewing FDA safety alerts of e.g., tapentadol and fentanyl				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1660	09/11/2014	EOS Archive 9/2/2014-11/20/2014	JAN-MS-03844401	JAN-MS-03844409		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1661	9/17/2014	Nucynta ER PADER May 2014-Aug 2014	JAN-MS-00228611	JAN-MS-00228611		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1662	09/17/2014	Sharp S, et al., Oklahoma Study of Incarcerated Mothers and Their Children, The University of Oklahoma Department of Sociology, 2014	ODOC-00004310	ODOC-00004357			
J1663	9/18/2014	Pharmacy Lock-In Referral Form				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1664	09/23/2014	FOR APPROVAL: Copy Revision Recommendations	JAN-MS-00753040	JAN-MS-00753043		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1665	9/26/2014	[Email] Slide deck from 9/26	JAN-MS-01971129	JAN-MS-01971154		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1666	9/29/2014	Opioid Prescribing Guidelines for Oklahoma Health Care Providers in the Office-Based Setting, Oklahoma State Department of Health				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1667	9/29/2014	[Email] Nucynta Speaker Programs	JAN-MS-01971128	JAN-MS-01971128		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1668	10/01/2014	[Email] Vortex II Post Diligence Questions	JAN-MS-02733170	JAN-MS-02733171		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1669	10/6/2014	PRC Meeting Agenda	JAN-MS-00997695	JAN-MS-00997696		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1670	10/06/2014	[Email] Nucynta Sales Deployment History	JAN-MS-02734351	JAN-MS-02734352		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1671	10/06/2014	DUR meeting packet, hydrocodone, S2 medication				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1672	10/7/2014	RADARS System Tapentadol Report Q2 2014	JAN-MS-01368869	JAN-MS-01369061		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1673	10/7/2014	2014 Notice of Registration, Bulk Manufacturer of Controlled Substances Application, Noramco, Inc.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1674	10/8/2014	DURB Meeting Packet	OKAG-00015189	OKAG-00015256		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1675	10/14/2014	PRC Meeting Agenda	JAN-MS-00997880	JAN-MS-00997880		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1676	10/27/2014	Letter from Oklahoma Health Care Authority to Pharmacists, Opioid Analgesic Quantity Limit - Short Acting Opioid Analgesics "No More Than 4"	OHCA-00005365	OHCA-00005365		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1677	11/7/2014	Email re: Opioid overdoses straining hospital ERs	OHCA-00005502			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1678	11/12/2014	DURB Meeting Packet	OKAG-00010964	OKAG-00011033		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	



TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1679	11/12/2014	DUR meeting packet re FDA news release approving labeling w/ADF - Embeda ER				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1680	12/1/2014	FW: Speaker FMV Analysis-Leveling	JAN-MS-00990298	JAN-MS-00990300		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1681	12/9/2014	NAVIPPRO Surveillance Report P2 2014 (5/1/2014-8/31/2014)	JAN-OK-00010115	JAN-OK-00010237		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1682	12/10/2014	DURB Meeting Packet, Dec. 10, 2014	OKAG-00011110	OKAG-00011183		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1683	12/10/2014	Re: Nucynta ER patient brochure revisions needed	JAN-MS-01102536	JAN-MS-01102537		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1684	12/10/2014	DUR meeting packet re FDA news release approving labeling w/ADF - Hysingla ER				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1685	12/17/2014	Re: Nucynta ER patient brochure revisions needed	JAN-MS-01069033	JAN-MS-01069035		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1686	12/31/2014	Oklahoma Opioid Prescribing Guidelines for Office-Based Setting				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1687	01/02/2015	Product Promotion Policy	JAN-MS-02898735	JAN-MS-00789755		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1688	1/7/2015	RADARS System Tapentadol Report Q3 2014	JAN-MS-01597449	JAN-MS-01597652		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1689	01/07/2015	Selected FDA Activities on Opioids, Pain Care Forum (Jan. 7, 2015) (OPMSL_EREV003_00304943)	OPMSL_EREV003_00304943			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1690	1/8/2015	Nucynta IR PADER Nov 2013-Nov 2014	JAN-MS-00235324	JAN-MS-00235324		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1691	1/11/2015	DUR meeting packet; FDA/DEA updates	OKAG-00011866			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1692	01/12/2015	Kolodny A., et al. The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction, Annual Review Public Health, 36, pp. 559-574, 2015				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1693	01/14/2015	[Email] Brand Playbook	JAN-MS-00430527	JAN-MS-00430528		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1694	01/26/2015	[Email] KOLs contacted by Med Affairs about the divestiture	JAN-MS-00576833	JAN-MS-00576833		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1695	1/27/2015	[Presentation] Medical Information Sales Training	JAN-MS-01971363	JAN-MS-01971364		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1696	01/28/2015	Email RE DEA's January 27-28, 2015 inspection of the Kentucky distribution center	JAN-MS-02984602	JAN-MS-02984607		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1697	1/29/2015	CNS Pain Team 2015 Call Plan Strategy	JAN-MS-01969583	JAN-MS-01969583		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1698	02/04/2015	[Email] Answering HCP Questions	JAN-MS-00430562	JAN-MS-00430563		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1699	2/5/2015	Fallin, lawmakers push compromise prescription bill	OKAG-00050481			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1700	02/18/2015	DEA - "DEA Issues Nationwide Alert on Fentanyl as Threat to Health and Public Safety" (18 Mar. 2015)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1701	02/19/2015	Home Study Training Calendar Nucynta ER and Nucynta	JAN-MS-00417287	JAN-MS-00417297		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1702	3/10/2015	Jane Ballantyne, Article entitled, "Preventing Prescription Opioid Abuse", JAMA, 03/10/2015, Vol. 313				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1703	03/11/2015	DURB Meeting Packet, Mar. 11, 2015	OKAG-00011345	OKAG-00011429		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1704	03/11/2015	Post DUR Meeting Notes	OHCA-00007439	OHCA-00007435		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1705	03/11/2015	DUR meeting packet re Retrospective Drug Evaluation re Safety & FDA safety alert about pain medicine				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1706	3/13/2015	[Presentation] Nucynta ER A Different Option for Chronic Pain Management	JAN-MS-01969722	JAN-MS-01969726		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1707	3/30/2015	FW: Community Connect Updated Materials	JAN-MS-00981690	JAN-MS-00981691		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1708	4/2/2015	Letter to FDA re Transfer of IND 61345 Ownership to Depomed - tapentadol	JAN-MS-02119925	JAN-MS-02119926		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1709	4/2/2015	Letter to FDA re Transfer of IND 108134 Ownership to Depomed - tapentadol oral solution	JAN-MS-02119927	JAN-MS-02119928		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1710	4/2/2015	Letter to FDA re Transfer of NDA 022304 Ownership to Depomed - Nucynta IR oral tablets	JAN-MS-02119929	JAN-MS-02119930		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1711	4/2/2015	Letter to FDA re Transfer of NDA 200533 Ownership to Depomed - Nucynta ER oral tablets	JAN-MS-02119931	JAN-MS-02119932		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1712	4/2/2015	Letter to FDA re Transfer of NDA 203794 Ownership to Depomed - Nucynta oral solution	JAN-MS-02119933	JAN-MS-02119934		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1713	4/7/2015	RADARS System Tapentadol Report Q4 2014	JAN-MS-01439894	JAN-MS-01440096		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1714	04/07/2015	Letter from Michael Levitt to unnamed business partner(s) enclosing suspicious order monitoring questionnaire	JAN-MS-02960561	JAN-MS-02960569		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1715	4/8/2015	DUR meeting packet; FY 2014 Annual Review				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1716	4/15/2015	NAVIPPRO Surveillance Report P3 2014 (9/1/2014-12/31/2014)	JAN-OK-00010238	JAN-OK-00010364		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1717	04/15/2015	DEA Distributors Conference Documents -2015	JAN-MS-03124022	JAN-MS-03124047		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1718	4/17/2015	RADARS System Tapentadol Report 2014 Annual	JAN-MS-01598670	JAN-MS-01598870		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1719	05/01/2015	DEA, 2018 Fentanyl Remains the Most Significant Synthetic Opioid Threat in US. May 01, 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1720	06/08/2015	DUR meeting packet, FDA release re buprenorphine Impact for treatment of opioid dependence				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1721	6/19/2015	Duragesic PBRER/PSUR May 2014-Apr 2015	JAN-MS-00291192	JAN-MS-00291192		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1722	06/19/2015	Janssen Benefit Risk Evaluation/Periodic Safety Update Report- Fentanyl	JAN-MS-00291192	JAN-MS-00291192		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1723	7/6/2015	Oklahoma State Board of Pharmacy Noramco Registration Renewal				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1724	07/08/2015	DURB Meeting Packet, Jul. 8, 2015	OKAG-00003808	OKAG-00003926		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1725	8/4/2015	Email from Robert Helfrick to Martha Wick, Nancy Miller, Maroun khater, et al.	JAN-MS-05433744	JAN-MS-05433745		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1726	08/19/2015	September 2015 DEA Manufacturers, Importers, Exporters conference email confirmation	JAN-MS-03124059	JAN-MS-03124062		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1727	10/07/2015	Drug Utilization Board Meeting Packet	OKAG-00006981	OKAG-00007133		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1728	10/26/2015	CDC - "CDC Health Advisory: Increases in Fentanyl Drug Confiscations and Fentanyl-Related Overdose Fatalities" (26 Oct. 2015)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1729	10/26/2015	Increases in Fentanyl Drug Confiscations and Fentanyl-related Overdose Fatalities Archived: October 26, 2015				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1730	10/27/2015	Email from Brown to Curtis et al re: fentanyl	OCME-00092481			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1731	10/30/2015	October 30, 2015 Supplement to Project Groundhog Management Presentation	JAN-OK-00149583	JAN-OK-00149587		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1732	11/01/2015	Enrolled House Bill No.1948 re public health and safety				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1733	11/30/2015	Email from Curtis to Nguyen	OCME-00092583			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1734	12/16/2015	DURB Meeting Packet, Dec. 16 2015	OKAG-00007724	OKAG-00007890		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1735	01/14/2016	Compton, Wilson M. - "Relationship Between Nonmedical Prescription-Opioid Use and Heroin Use" (14 Jan. 2016)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1736	01/28/2016	CMCS Bulletin. Best Practices for Addressing Prescription Opioid Overdoses, Misuse and Addiction from Vikki Wachino, CMCS				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1737	02/02/2016	CMCS Bulletin. Best Practices for Addressing Prescription Opioid Overdoses, Misuse and Addiction <a href="https://www.medicaid.gov/federal-policy-guidance/downloads/clb-02-02-16">https://www.medicaid.gov/federal-policy-guidance/downloads/clb-02-02-16</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1738	2/9/2016	Andrew Kolodny, Article entitled, "Opioids are Rarely the Answer," NY Times, 02/09/2016				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1739	3/9/2016	DURB Meeting Packet	OKAG-00008237	OKAG-00008347		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1740	03/09/2016	DUR meeting packet, FDA safety alert re children taking tramadol/Ultram				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1741	03/14/2016	Post DUR Meeting Notes	OHCA-00002406	OHCA-00002408		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1742	03/18/2016	Centers for Disease Control and Prevention, "CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016," MMWR (Mar. 18, 2016)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1743	03/18/2016	MMWR: CDC Guideline for Prescribing Opioids for Chronic Pain—United States				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1744	03/23/2016	T. Phillips, Terrell, Oklahoma Doctor: One Way to Help Curb Misuse of Opioids (Mar. 23, 2016)	OSBVME-00028013			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1745	3/31/2016	Oklahoma State Board of Pharmacy Noramco Registration Renewal				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1746	04/04/2016	May 2016 DEA Distributor Conference email confirmation and agenda	JAN-MS-03124053	JAN-MS-03124055		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1747	04/12/2016	April 2016 DEA Pharma Training Seminar	JAN-MS-03124056	JAN-MS-03124058		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1748	04/13/2016	DURB Meeting Packet, Apr. 13, 2016	OKAG-00008351	OKAG-00008520		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1749	04/26/2016	Frieden T, Houry D., Reducing the Risks Relief —The CDC's Opioid-Prescribing Guideline. New England Journal of Medicine, 374(16), 1501–1504, 2016				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1750	05/25/2016	Mimi Yagoub, "Why a 900% Spike in Murders in West Mexico State," InSight Crime, 25 May 2016.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1751	06/08/2016	DURB Meeting Packet, Jun. 8, 2016	OKAG-00010215	OKAG-00010394		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1752	6/8/2016	John R. Roby, Article entitled, "Expert Talks about Opioids," Press & Sun-Bulletin (Binghamton, New York), 1st edition, 06/08/2016				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1753	6/23/2016	Duragesic PBRER/PSUR May 2015-Apr 2016	JAN-MS-00291230	JAN-MS-00291230		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1754	06/23/2016	Duragesic PBRER/PSUR May 2015-Apr 2016	JAN-MS-00291230	JAN-MS-00291230		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1755	07/13/2016	DURB Meeting Packet, Jul. 13, 2016	OKAG-00008610	OKAG-00008749		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1756	07/13/2016	Post DUR Meeting Notes	OHCA-00337365	OHCA-00337367		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1757	08/09/2016	13 WHAM ABC, "WNY drug bust operation lands \$2.5 million in cocaine, heroin, fentanyl," 9 August 2016.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1758	8/10/2016	Email re: Quick Question	OHCA-00423837			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1759	08/16/2016	Huntington Police Respond to 26 Overdoses in 4 Hours. Clark Davis. August 16, 2016.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1760	08/26/2016	Gladden, Matthew R. - "Fentanyl Law Enforcement Submissions and Increases in Synthetic Opioid-Involved Overdose Deaths—27 States, 2013-2014" (26 Aug. 2016)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1761	9/1/2016	Email re influx of fentanyl-laced counterfeit pills	OSDH-01373757			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1762	09/13/2016	InSightCrime. US Singles Out Bolivia Venezuela Counternarcotic Failures. Venezuela Investigative Unit. September 13, 2016.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1763	9/14/2016	DUR meeting packet; Concomitant Opioid and Benzo Use; FDA/DEA Updates	OKAG-00010793			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1764	09/14/2016	DUR meeting packet, unanimous vote to accept CoP recs re opioid education				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1765	10/05/2016	Drug Utilization Board Meeting Packet	OKAG-00007137	OKAG-00007286		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1766	10/11/2016	InSightCrime. Peru Renews Military Operations in Vraem Coca Hub. Tristan Clavel. October 11, 2016				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1767	10/12/2016	DURB Meeting Packet	OKAG-00007137	OKAG-00007286		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1768	10/12/2016	DUR meeting packet, re 90-day supply of S2 narcs				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1769	11/09/2016	DUR meeting packet, re suboxone utilization				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1770	12/05/2016	Email from Pam J. Archer to Tracy Wendling and Claire Nguyen	OSDH-01374935	OSDH-01374943		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1771	12/9/2016	Email from Castleberry to Chief Medical Officer (CMO)	ODOC-00018265			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1772	12/14/2016	Email re: News-9 Article	OBN-00203794			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1773	12/20/2016	Email and drug deaths re drug deaths	OSDH-01578349, OSDH-01578352			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1774	12/21/2016	Email from Eric Pfeifer to NAME Listserv and Mitchell Weinerg	OCME-00147966			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1775	12/30/2016	Rudd, Rose A. - "Increases in Drug and Opioid-Involved Overdose Deaths—United States, 2012–2015"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1776	12/30/2016	Article entitled, "Increases in Drug and Opioid-Involved Overdose Deaths - United States, 2010-2015"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1777	12/31/2016	"QuintilesIMS Thirteenth Amendment to Information Services Agreement No. COBS-0608-1213"	JAN-MS-03108834	JAN-MS-03108835		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1778	12/31/2016	"QuintilesIMS Thirteenth Amendment to Information Services Agreement No. COBS-0608-1213"	JAN-MS-03109045	JAN-MS-03109046		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1779	01/01/2017	"QuintilesIMS Fourteenth Amendment to Information Services Agreement No. COBS-0608-1213"	JAN-MS-03108836	JAN-MS-03108858		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1780	01/28/2017	Christopher J. Ruhm, Drug involvement in fatal overdoses, SSM - Population Health, Vol. 3, pp. 219-226, 2017				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1781	02/14/2017	Mike Gallagher, "The Cartels Next Door: 'Mayor of Mexico' ran a slick operation," Albuquerque Journal, 14 February 2017.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1782	02/16/2017	Frank, Richard G. - "Addressing the Fentanyl Threat to Public Health" (16 Feb. 2017)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1783	02/26/2017	Pedro Villa y Caña, "Puertos. Marina recupera el control de capitanías," El Universal				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1784	02/26/17	Email from Mark Reynolds to Terri White et al.	ODMHSAS-00161254	ODMHSAS-00161255		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1785	02/28/2017	The Feds Are About to Stick It to Pain Patients in a Big Way, Vice				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1786	3/2017	United States Department of State. Bureau of International Narcotics and Law Enforcement Affairs. International Narcotics Control Strategy Report. Volume I Drug and Chemical Control.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1787	3/8/2017	DURB Meeting Packet	OKAG-00009675	OKAG-00009782		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1788	03/08/2017	DUR meeting packet, FDA Safety Update re death, opioids/benzos				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1789	03/09/2017	Memorandum from Melissa Abbott to Nancy Nesser				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	



TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS [Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them]
J1790	03/22/2017	DEA Pharma Training Seminar Agenda	JAN-MS-03124050	JAN-MS-03124052		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1791	04/12/2017	DURB Meeting Packet, Apr. 12, 2017	OKAG-00009783			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1792	04/26/2017	Press Release: Attorney General Mike Hunter Announces Formation of the Oklahoma Commission on Opioid Abuse. OK Office of the Attorney General Mike Hunter				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1793	5/5/2017	Email from Fain to Harrison	OSBP00086356			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1794	05/08/2017	Pew, As Fentanyl Spreads, States Step Up Responses				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1795	5/10/2017	DURB Meeting Packet	OKAG-00010094	OKAG-00010214		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1796	5/10/2017	DURB Meeting Packet	OKAG-00013226	OKAG-00013302		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1797	05/10/2017	DUR meeting packet, FDA Drug Safety Comm'n re restriction of tramadol in children				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1798	05/23/2017	Georgetown University Center on Health Insurance Reforms Website: <a href="http://chirblog.org/responding-opioid-crisis-insurers-balance-stepped-monitoring-restrictions-need-appropriate-pain-treatment/">http://chirblog.org/responding-opioid-crisis-insurers-balance-stepped-monitoring-restrictions-need-appropriate-pain-treatment/</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1799	05/23/2017	Georgetown University Center on Health Insurance Reforms. Palanker D. Ahn S, Corlette S. Responding to the Opioid Crisis: Insurers Balance Stepped up Monitoring, Restrictions with Need for Appropriate Pain Treatment. May 23, 2017				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1800	05/25/2017	InSight Crime interview, Public Health advocate, 12 June 2018. 132 US Department of Homeland Security, "Testimony of Robert E. Perez, Executive Assistant Commissioner," 25 May 2017.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1801	05/29/2017	InSightCrime. What Can Bolivia Teach Post Conflict Colombia About Coca Reduction? David Gagne. Mayo 29, 2017.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1802	06/07/2017	Brown University. Feared by drug users but hard to avoid, fentanyl takes a mounting toll. June 7, 2017.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1803	6/8/2017	Email and attachment re Fentanyl	OSDH-00666428, OSDH-00665932			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1804	06/08/2017	Sacco, Lisa - "Economic Aspects of the Opioid Crisis"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1805	6/15/2017	Duragesic PBRER/PSUR May 2016-Apr 2017	JAN-MS-00291322	JAN-MS-00291322		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1806	6/15/2017	Email re Drug fact sheets/fentanyl	OBN-00070701			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1807	06/15/2017	Duragesic PBRER/PSUR May 2016-Apr 2017	JAN-MS-00291322	JAN-MS-00291322		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1808	06/19/2017	Oklahoma Drug Threat Assessment 2017	OBN-00006730	OBN-00006766		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1809	06/19/2017	Oklahoma Drug Threat Assessment 2017	OBN-00001848	OBN-00001882		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1810	06/19/2017	JOM Customer Service New Customer Pre Application	JAN-MS-03121163	JAN-MS-03121165		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1811	06/19/2017	OK Drug Threat Assessment	OBN-00006730	OBN-00006766		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1812	6/22/2017	Negin Hadaghian, Article entitled, "Transcript: Addiction in America," Washington Post, 06/22/2017				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1813	6/30/2017	Complaint_Cleveland County, State of Oklahoma AG v. Purdue Pharma L.P. et al.,				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1814	07/01/2017	"QuintilesIMS Fifteenth Amendment to Information Services Agreement No. COBS-0608-1213"	JAN-MS-03108831	JAN-MS-03108833		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1815	7/10/2017	McNutt, K.S., NewsOK, Oklahoma Medical School's Training Doctors to Battle Opioid Crisis				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1816	07/12/2017	DURB Meeting Packet, Jul. 12, 2017	OKAG-00010602	OKAG-00010792		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1817	07/12/2017	Drug Utilization Board Meeting Packet	OKAG-00010602	OKAG-00010792		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1818	07/17/2017	Post Drug Utilization Board Meeting Notes	OHCA-00085862	OHCA-00085864		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1819	7/19/2017	Transcript of Round Table Discussion on Opioid Epidemic in Oklahoma, moderated by Mr. Ted Streuli, Opioid Epidemic Roundtable, The Journal Record				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1820	08/10/2017	JOM Customer Support Services New Customer Request Process	JAN-MS-03121284	JAN-MS-03121290		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1821	08/22/2017	El tiempo. Un jefe del Eln es el gran capo de la heroína en el país. Justicia. August 22, 2017.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1822	08/23/2017	Phil Fairbanks, "New indictment ups the ante for WNY drug network linked to Mexican cartel," The Buffalo News				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1823	08/23/2017	Alex Hollingsworth, et al., Macroeconomic conditions and opioid abuse, Journal of Health Economics, Vol. 56, pp. 222-233, 2017				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1824	08/28/2017	InSightCrime. Bolivian, Peru Cocaine Figures Show Colombia Driving Andean Boom. Parker Asmann. August 28, 2017.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1825	08/29/2017		OKAG-00134719			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1826	09/01/2017	Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report Weekly / Vol. 66 / No. 34 September 1, 2017.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1827	09/01/2017	Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report Weekly / Vol. 65 / No. 34 September 1, 2017.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1828	9/10/2017	Tusla World Article: Fentanyl shows up in counterfeit pills in Oklahoma	OCME-00087234			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1829	9/13/2017	DUR meeting recording and transcription	OUCDP-00038957			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1830	9/13/2017	DUR meeting packet; Opioid Utilization Comparison	OKAG-00005307			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1831	09/13/2017	Post DUR Meeting Notes	OHCA-00000525	OHCA-00000527		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1832	09/13/2017	DUR meeting minutes, Vote to PA ADFs				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1833	9/14/2017	DURB Meeting Packet	OKAG-00010793	OKAG-00010910		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1834	09/29/2017	Email to Laura Pittman from Teresa Croom	ODOC-00033256	ODOC-00033257		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1835	10/01/2017	US Drug Enforcement Administration, "2017 National Drug Threat Assessment," 1 October 2017				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1836	10/4/2017	DURB Meeting Packet	OKAG-00005085	OKAG-00005306		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1837	10/06/2017	IOM Customer Support Services - Business Manager: Release Orders	JAN-MS-03121291	JAN-MS-03121311		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1838	10/10/2017	DURB Meeting Packet	OKAG-00007348	OKAG-00007415		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1839	10/17/2017	InSight Crime interview, Kentucky law enforcement official, 17 July 2018. 124 US Department of Justice, "Justice Department announces indictments against Chinese manufacturers of fentanyl and other opiate Substances," 17 October 2017				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1840	10/17/2017	US Department of Justice, "Justice Department announces indictments against Chinese manufacturers of fentanyl and other opiate Substances,"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1841	10/24/2017	Email re POC at OBN	OBN-00052737			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1842	10/24/2017	Andrew Kolodny et al., Article entitled, "Ten Steps the Federal Government Should Take Now to Reverse the Opioid Addiction Epidemic," JAMA, American Medical Association, Vol. 318, Number 16, 10/24/31, 2017				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1843	11/01/2017	US President's Office, "The President's Commission on Combating Drug Addiction and the Opioid Crisis," 1 November 2017.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1844	11/01/2017	The President's Commission on Combating Drug Addiction and the Opioid Crisis, Report 2017				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1845	11/03/2017	O'Donnell, Julie K. - "Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700—10 States, July-December 2016" (3 Nov. 2017)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1846	11/15/2017	US House Committee on Energy and Commerce, "Bipartisan E&C Leaders Press DEA on Use of Pill Presse in Fentanyl Pill Mills," 15 November 2017.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1847	11/16/2017	JOM Customer Support Services DEA Unusual Order Report and Monitoring Process	JAN-MS-05433731	JAN-MS-05433740		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1848	11/30/2017	Emails re cyclopropyl fentanyl	OSDH-00474210			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1849	11/30/2017	Max Blau, Article entitled "FDA approves Indivior's Monthly Injection to Treat Opioid Addiction," STAT, 11/30/2017				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1850	12/06/2017	Andrew Kolodny, Article entitled, "What Hillary Clinton could do about the Opioid Crisis," Huffington Post, 12/06/2017				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1851	12/13/2017	DURB Meeting Packet, Dec. 13, 2017	OKAG-00009251	OKAG-00009392		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1852	12/13/2017	DUR meeting pscket, re FDA News Release opioid use disorder				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1853	12/15/2017	Email from Penney Cowan to Peg Forrestel RE: Growing Pains	JAN-MS-00396535				
J1854	12/20/2017	Email from Robert Helfrick to Stephanie Dixon, Josee Bourgoin, Liz Allison, et al.	JAN-MS-03124006	JAN-MS-03124007		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1855	12/21/2017	Lopez, G. - "How fentanyl became America's leading cause of overdose deaths" 17 (21 Dec. 2017).				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1856	12/28/2017	Email from Robert Helfrick to Stephanie Dixon, Josee Bourgoin, Liz Allison, et al.	JAN-MS-03124010	JAN-MS-03124011		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1857	1/2018	U.S. Senate, Permanent Subcommittee on Investigations - "Combatting the Opioid Crisis: Exploiting Vulnerabilities in International Mail"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1858	1/2/2018	Don Sapatkin, Article entitled, "A Grim Forecast Five Addiction Experts Weigh in on the Future of the Opioid Crisis." Tribune News Service, 01/02/2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1859	1/8/2018	January 1, 2018 Kolodny Tweet				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1860	01/17/2018	Drugs for dollars: How Medicaid helps fuel the opioid epidemic, Majority Media				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1861	01/19/2018	InSightCrime. News Analysis European Cocaine Seizures Hint at New Possibilities for Colombia Traffickers. James Bargent. January 19, 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1862	01/22/2018	Burns, Gus - "Detroit Police Join Task Force in Response to 383 Opioid-Related Deaths in 2017" ( 22 Jan. 2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1863	1/23/2018	Dr. James Turrentine Confirmed Quality Concern	OHCA-00138364			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1864	01/23/2018	US Senate Committee on Homeland Security and Governmental Affairs, Permanent Subcommittee on Investigations: Staff Report, "Combatting the Opioid Crisis: Exploiting Vulnerabilities in International Mail," 23 January 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1865	01/23/2018	The Oklahoma Commission on Opioid Abuse, Final Report, January 23, 2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1866	1/24/2018	Scott, D. - "This is how easy it is to order deadly opioids over the internet". Available at: <a href="https://www.vox.com/policy-and-politics/2018/1/24/16928986/fentanyl-online-orders-postal-service">https://www.vox.com/policy-and-politics/2018/1/24/16928986/fentanyl-online-orders-postal-service</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1867	1/29/2018	Re: Proffer by Russell K. Portenoy, M.D.	PLTF_2804_0000044	PLTF_2804_000004440		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1868	01/29/2018	ACI Summit on Controlled Substances Agenda	JAN-MS-03124048	JAN-MS-03124049		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1869	02/05/2018	Massachusetts Department of Public Health, Drug Formulary Commission, minutes of meeting on February 5, 2018, available at <a href="https://www.mass.gov/files/documents/2018/05/11/dfc-minutes-2-5-18-approved.pdf">https://www.mass.gov/files/documents/2018/05/11/dfc-minutes-2-5-18-approved.pdf</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1870	02/05/2018	Massachusetts Public Health Commission (Formulary). Minutes from public meeting on February 5, 2018. Joshua P. Cohen presentation on abuse-deterrent formulations of opioid analgesics				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1871	02/05/2018	Massachusetts Public Health Commission (Formulary). Minutes from public meeting on February 5, 2018. Joshua P. Cohen presentation on abuse-deterrent formulations of opioid analgesics				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1872	02/13/2018	New York Times. Meth, the Forgotten Killer, is Back. And It's Everywhere. Frances Robles. February 13, 2018. Available at: <a href="https://www.nytimes.com/2018/02/13/us/meth-crystal-drug.html">https://www.nytimes.com/2018/02/13/us/meth-crystal-drug.html</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1873	02/14/2018	DURB Meeting Packet, Feb. 14, 2018	OKAG-00009524	OKAG-00009673		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1874	02/14/2018	DUR's meeting packet	OKAG-00009524	OKAG-00009674		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1875	03/01/2018	InSightCrime. UN Drug Control Board Emphasizes Prevention Treatment in New Report. Mike LaSusa. March 1, 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1876	3/2018	U.S. Government Accountability Office - "Illicit Opioids: While Greater Attention Given to Combating Synthetic Opioids, Agencies Need to Better Assess Their Efforts"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1877	3/2018	United States Department of State. Bureau for International Narcotics and Law Enforcement Affairs. International Narcotics Control Strategy Report. Volume I. Drug and Chemical Control. Available at: <a href="https://www.state.gov/documents/organization/278759.pdf">https://www.state.gov/documents/organization/278759.pdf</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1878	3/5/2018	Settlement Agreement between Dr. Russell Portenoy and MDL Plaintiffs	PLTF_2804_0000044	PLTF_2804_000004422		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1879	03/07/2018	Drug Utilization Board Review Meeting Packet	OKAG-00004601	OKAG-00004722		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1880	3/8/2018	U.S. Attorney's Office, US Southern District of Ohio, "Twelve Charged in Cincinnati in Connection to Mexico-Based Sinaloa Drug Cartel,"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1881	03/14/2018	FDA, Center for Drug Evaluation and Research Presentation: FDA's Actions to Address the Opioid Epidemic, March 2018, available at <a href="https://www.fda.gov/downloads/AboutFDA/CentersOfficer/OfficeofMedicalProductsandTobacco/CDER/UCM601178.pdf">https://www.fda.gov/downloads/AboutFDA/CentersOfficer/OfficeofMedicalProductsandTobacco/CDER/UCM601178.pdf</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1882	03/14/2018	DURB Meeting Packet, Mar. 14, 2018	OKAG-00004601	OKAG-00004722		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1883	03/15/2018	InSightCrime. The "Invisibles": Colombia's New Generation of Drug Traffickers. Jeremy McDermott. March 15, 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1884	03/22/2018	InSightCrime. Colombia's Last Guerrillas Escalate Battle Contol. Angelika Albaladejo. March 22, 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1885	03/23/2018	NYC Health. Health Department Pilots Awareness Campaign in Lower East Side Bars and Nightclubs on Risk of Fentanyl in Cocaine Supply. May 23, 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1886	03/27/2018	Medicare is Cracking Down on Opioids. Doctors Fear Pain Patients Will Suffer, New York Times				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1887	03/27/2018	Hoffman J. Medicare is Cracking Down on Opioids. Doctors Fear Pain Patients Will Suffer. New York Times. March 27, 2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1888	03/28/2018	Commission on Security and Cooperation in Europe: US Helsinki Commission, "The Opioid Crisis and the Dark Web: How Transnational Criminal Devastate US Communities," 28 March 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1889	03/29/2018	NPR. Fentanyl-Laced Cocaine Becoming A Deadly Problem Among Drug Users. March 29, 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1890	03/29/2018	Karik, A., Blue Cross and Blue Shield Discourages Use of Opioids in Primary Care Treatment, Modern Healthcare, March 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1891	4/9/2018	Re: Proffer by Perry Fine, M.D.	PLTF_2804_0000045	PLTF_2804_000004547		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1892	4/9/2018	Re: Proffer by Scott Fishman, M.D.	PLTF_2804_0000045	PLTF_2804_000004549		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1893	4/9/2018	Re: Proffer by Lynn Webster, M.D.	PLTF_2804_0000045	PLTF_2804_000004551		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1894	04/11/2018	Henry J. Kaiser Family Foundation Website: <a href="https://www.kff.org/medicaid/issue-brief/the-opioid-epidemic-and-medicaids-role-in-facilitating-access-to-treatment/">https://www.kff.org/medicaid/issue-brief/the-opioid-epidemic-and-medicaids-role-in-facilitating-access-to-treatment/</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1895	04/11/2018	DURB Meeting Packet, Apr. 11, 2018	OKAG-00009939	OKAG-00010093		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	



TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1896	04/11/2018	Julia Zur, Jennifer Tolbert, The Opioid Epidemic and Medicaid's Role in Facilitating Access to Treatment, Henry J. Kaiser Family Foundation (Apr. 11, 2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1897	04/11/2018	DUR's meeting packet	OKAG-00009939	OKAG-00010093		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1898	04/16/2018	Castlight, Barbee G. April 20, 2016. Breaking Down Opioid Abuse Trends in America's Workforce.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1899	4/17/2018	Publication, entitled, "Government Actions to Curb the Opioid Epidemic;" Response to Ten Steps the Federal Government Should Take Now to Reverse the Opioid Addiction Epidemic, JAMA, 04/17/2018, 319(15), pp. 1619-1620				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1900	04/19/2018	Coscarella, J. - "Prince's Overdose Death Results in No Criminal Charges" (19 April 2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1901	04/27/2018	InSight Crime interview, Mike Vigil, 27 April 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1902	04/28/2018	ICER website: ICER Final Report on "Abuse-Deterrent" Opioids Highlights Uncertainty About Real-World Impact, Short-Term Risk of Shifting Abuse to More Dangerous Drugs, and High Added Costs, Institute for Clinical and Economic Review, August 8, 2017, available at <a href="https://icer-review.org/announcements/final-adf-report">https://icer-review.org/announcements/final-adf-report</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1903	04/30/2018	Andrew Kolodny, Testimony before House Energy and Commerce Committee, Health Subcommittee Hearing on Combating the Opioid Crisis, Enforcement and Patient Safety, April 30, 2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1904	5/2/2018	The Atlantic. The Hard-to-Trace Ingredient Behind Skyrocketing Cocaine Deaths. Joseph Frankel				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1905	05/04/2018	Lopez, G. - "Why America's cocaine problem is now a fentanyl problem too" (4 May 2018).				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1906	5/4/2018	Why America's cocaine problem is now a fentanyl problem too., Vox Media, German Lopez, May 4, 2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1907	05/04/2018	JOM Customer Support Services Schedule 11-V Order Processing and Investigating Questionable Order Quantities	JAN-MS-03121360	JAN-MS-03121368		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1908	05/07/2018	Cohen J. Guest Commentary: Aligning price and value for drugs—potential disrupters of the PBM model. Modern Healthcare. May 7, 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1909	5/10/2018	United States Senate Committee on Homeland Security and Governmental Affairs, Minority Staff Report, "Combating the Opioid Epidemic: Intercepting Illicit Opioids at Ports of Entry,"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1910	05/10/2018	US Senate Committee on Homeland Security and Governmental Affairs, Minority Staff Report, "Combating the Opioid Epidemic: Intercepting Illicit Opioids at Ports of Entry," 10 May 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1911	05/14/2018	Alison Fox, "China's fentanyl production, export fueling US opioid crisis, Schumer says," AM New York, 14 May 2018. <a href="https://www.amny.com/news/china-fentanyl-schumer-1.18531808">https://www.amny.com/news/china-fentanyl-schumer-1.18531808</a> 14 US-China Economic and Security Review Commission, "Fentanyl: China's Deadly Export to the United States," February 2017.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1912	5/16/2018	Effect of a high dosage opioid prior authorization policy on prescription opioid use, misuse, and overdose outcomes				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1913	05/17/2018	JOM Customer Support Services Schedule II CS Order Process	JAN-MS-03121245	JAN-MS-03121264		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1914	05/22/2018	Letter from Colleen Learch (Vice President, Avalere) to Jeff Smith (Vice President, J&J) re RFP Primer	JAN-OK-00148790	JAN-OK-00148794		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1915	06/02/2018	InSight Crime interview, high ranking official, Mexico's Attorney General's Office, 2 June 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1916	06/04/2018	Wynn, R.L. - "Nonmedical Prescription Opioid Users Transitioning to Heroin: Incidence and Predictors"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1917	06/05/2018	FDA - "FDA takes action against 53 websites marketing unapproved opioids as part of a comprehensive effort to target illegal online sales" (5 June 2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1918	06/05/2018	InSight Crime interview, US government official, 5 June 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1919	06/05/2018	Rachel Martin, "In Rural Ohio, An Opioid Crisis Becomes a Methamphetamine Crisis," National Public Radio				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1920	6/7/2018	Terry DeMio, "Fentanyl deaths up 1,000% since 2013, so much so that even heroin's supply is dwarfed," The Cincinnati Enquirer				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1921	06/13/2018	Martin, James - "Effect of Restricting the Legal Supply of Prescription Opioids on Buying Through Online Illicit Marketplaces: Interrupted Time Series Analysis" (13 June 2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1922	06/14/2018	Questionable Order Justification Release Form	JAN-MS-05433757	JAN-MS-05433757		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1923	06/22/2018	Mark Stevenson, "Mexico opium poppy growers see price drop, turn to marijuana," AP News, 22 June 2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1924	06/22/2018	Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage and Commercial Insurers				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1925	06/25/2018	CNBC, "China says the US domestic opioid market is the crux of the crisis," 25 June 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1926	6/26/2018	Email: Opioids overdoses and withdraw medication	DKNB-00005953			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1927	06/26/2018	InSightCrime. Colombia Coca Production Hits New Record High US Figures Say. Parker Asmann. June 26, 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1928	06/26/2018	Questionable Order Justification Release Form	JAN-MS-05433755	JAN-MS-05433755		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1929	06/27/2018	FDA - "FDA Commissioner Scott Gottlieb, M.D., Invites Internet Stakeholders to Opioid Summit" (27 June 2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1930	6/28/2018	US Customs and Border Protection, "Philadelphia CBP Seizes Nearly \$1.7 Million in Fentanyl Shipped from Chin,"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1931	07/03/2018	June S. Beittel, "Mexico: Organized Crime and Drug Trafficking Organizations," Congressional Research Service, 3 July 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1932	7/5/2018	JOM Customer Support Services DEA Questionable Order Report and Monitoring Process	JAN-MS-03121171	JAN-MS-03121185		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1933	7/6/2018	Oklahoma State Board of Pharmacy Noramco Registration Renewal				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1934	07/06/2018	InSight Crime interview, Vancouver public health official, 6 July 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1935	07/09/2018	Gottlieb, Scott - "Statement by FDA Commissioner Scott Gottlieb, M.D., on balancing access to appropriate treatment for patients with chronic and end-of-life pain with need to take steps to stem misuse and abuse of opioids" (9 July 2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS [Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them]
J1936	7/11/2018	DUR meeting packet; SoonerCare Opioid Initiative Update; Annual Review				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1937	7/11/2018	DUR meeting recording and transcription	OUCOP-00038979			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1938	7/11/2018	DUR meeting packet; SoonerCare Opioid Initiative Update; Annual Review				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1939	07/11/2018	InSight Crime interview, Ohio law enforcement official, 11 July 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1940	07/11/2018	DUR meeting packet, CoP recommending 100 MME guideline				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1941	7/12/2018	U.S. Attorney's Office, US Southern District of California, "Former Border Patrol Agency Pleads Guilty to Conspiracy to Distribute 4ANPP Used in the Manufacturing of Fentanyl,"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1942	7/16/2018	Oklahoma State Board of Pharmacy Noramco Registration Renewal				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1943	07/16/2018	InSight Crime interview, Kentucky law enforcement official, 16 July 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1944	07/16/2018	InSightCrime. Cocaine Leaving Ecuador Shows Flaws Anti-Drug Strategies. Felipe Puerta. July 16, 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1945	07/17/2018	Dan Goldberg, "Evolving Opioid Epidemic Poses Challenge for Public Health Officials," Politico, 17 July 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1946	07/17/2018	InSight Crime interview, Pittsburgh treatment provider, 7 June 2018. 106 Dan Goldberg, "Evolving Opioid Epidemic Poses Challenge for Public Health Officials," Politico, 17 July 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1947	07/19/2018	Cohen J. "Diseases of Despair" Contribute To Declining U.S. Life Expectancy. Forbes. Jul. 19, 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1948	07/20/2018	Luis Herrera, "El Cartel de los Océanos," Reporte Índigo, 20 July 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1949	07/22/2018	InSight Crime interview, Federal Police officials, 22 July 2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1950	07/23/2018	Parker Asmann, "Mexico Organized Crime-Related Executions Hit Record High: Report," 26 July 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1951	07/26/2018	InSight Crime email correspondence, DEA official, 26 July 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1952	07/26/2018	InSightCrime. Mexico, China are key nodes in fentanyl trade DEA. Mike LaSusa. July 26, 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1953	8/1/2018	Settlement Agreement between Dr. Fishman and MDL Plaintiffs	PLTF_2804_0000045	PLTF_2804_000004526		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1954	8/2018	Pham, et al., Overview of Prescription Opioid Deaths in the Oklahoma State Medicaid Population, 2012-2016, Medical Care Vol. 56 No. 8				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1955	08/02/2018	Department of Justice. U.S. Attorney's Office. Southern District of California. 19-Year-Old Charged With Importation of 11,490 Fentanyl Pills, 61 Pounds of Methamphetamine, and 14 Pounds of Heroin at San Ysidro Port of Entry. August 2, 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1956	08/07/2018	Naloxone: How overdose-reversing drug saved Demi Lovato and thousands more				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1957	08/08/2018	Department of Justice. U.S. Attorney's Office. Southern District of California. Defendant Charged with Importation of More than 20,000 Fentanyl Pills at the San Ysidro Port of Entry. August 8, 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1958	08/08/2018	Abuse-Deterrent Formulations of Opioids: Effectiveness and Value Final Evidence Report. Institute for Clinical and Economic Review. Aug. 8, 2017.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1959	08/14/2018	How Oxycodone Gets Laced With Fentanyl. August 14, 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1960	08/22/2018	El Espectador. Así se mueve la heroína por las carreteras del país Judicial. Catalina Vargas Vergara. August 22, 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1961	08/23/2018	InSightCrime. Shifting Ex Farc Mafia Alliances Fuel Colombia Criminal Shakeup. Parker Asmann and James Bargent. August 23, 2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1962	08/28/2018	Table of Post-Marketing Requirement Letters that Were Reissued on 06 February 2016				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1963	08/31/2018	MySA. An Ordinary Couple Who Drove Raggedy Cars. Guillermo Contreras. August 31, 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1964	09/04/2018	Cohen J. Medicaid To Introduce Value-Based Drug Pricing. Forbes. Sep. 4, 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1965	09/06/2018	Department of Justice. Tackling Fentanyl: The China Connection, presented September 6, 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1966	09/07/2018	JOM Controlled Substance Compliance Maintaining DEA and State Reporting	JAN-MS-03121312	JAN-MS-03121326		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1967	9/13/2018	CDC: 50 Million Americans Have Chronic Pain, Pain News Network				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1968	09/13/2018	CDC: 50 Million Americans Have Chronic Pain, Pain News Network				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1969	9/14/2018	CDC Morbidity and Mortality Weekly Report, Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults -- United States, 2016				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1970	09/14/2018	Fox 5. 3 die from fentanyl-laced cocaine in beach areas. Sandra Phillips, September 14, 2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1971	09/14/2018	CDC Morbidity and Mortality Weekly Report, Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults -- United States, 2016				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1972	09/19/2018	U.S. Department of Health and Human Services, Facing Addiction in America, The Surgeon General's Spotlight on Opioids				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1973	09/19/2018	Oklahoma Bureau of Narcotics and Oklahoma General Presentation				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1974	9/24/2018	Settlement Agreement between Dr. Fine and MDL Plaintiffs	PLTF_2804_0000044	PLTF_2804_000004506		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1975	9/24/2018	Settlement Agreement between Dr. Webster and MDL Plaintiffs	PLTF_2804_0000045	PLTF_2804_000004545		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1976	09/24/2018	Cohen J. To Include Or Not Include Drug Prices in DTC Ads. Sep. 24, 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1977	09/25/2018	Email from Georgly Gurainik re: DEA inspection of FDC	JAN-MS-05433746	JAN-MS-05433747		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1978	09/28/2018	Hindustan Times, "Three including Mexican arrested with drugs worth over Rs 100 crore in MP," 28 September 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1979	10/2018	"Editorial: Pain, Opioids, and Suicide Mortality in the United States," Annals of Internal Medicine				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1980	10/01/2018	JOM Distribution Shipping Process	JAN-MS-03121186	JAN-MS-03121244		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1981	10/02/2018	Sandoe E, Fry C, Frank R. Policy Levers That States Can Use To Improve Opioid Addiction Treatment And Address The Opioid Epidemic, Health Affairs Blog				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1982	10/12/2018	U.S. Attorney's Office, US Northern District of Ohio, "Twenty people indicted in conspiracy that brought large amounts of heroin, cocaine and fentanyl to Northeast Ohio,"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1983	10/13/2018	International Association of Counseling Services, Inc., Standards for University and College Counseling Services, October 13, 2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1984	10/16/2018	Ezequiel Flores Contreras, "Sierra de Guerrero: la amapola a la baja, la violencia al alza," Proceso, 16 October 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1985	10/18/2018	InSightCrime. Peru Drug Trafficking Expanding European Markets. Anna Grace. October 18, 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1986	10/24/2018	JOM Customer Support Services Monthly Metric Report for Scheduled Orders	JAN-MS-03121265	JAN-MS-03121283		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1987	10/26/2018	InSight Crime interview, Kentucky law enforcement official, 17 July 2018. 128 US-China Economic and Security Review Commission, "Fentanyl Flows from China: An Update since 2017," 26 November 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1988	10/31/2018	Prescribing Policies: States Confront Opioid Overdose Epidemic, National Conference of State Legislatures				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1989	11/01/2018	Deposition of A. Harrell, Pharm. D., Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Nov. 1, 2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1990	11/02/2018	ONDCP. ONDCP Releases Data on Coca Cultivation and Cocaine Production in Peru and Bolivia. November 2, 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1991	11/02/2018	Deposition of Paul L. Preslar, D.O., Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Nov. 2, 2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1992	11/04/2018	Janssen Presentation: JOM Suspicious Order Monitoring PowerPoint	JAN-MS-03089466	JAN-MS-03089483		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1993	11/4/2018	Andrew Kolodny Tweet, November 4, 2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1994	11/07/2018	Deposition of James P. Osborne, Pharm. D., Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Nov. 7, 2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1995	11/08/2018	Deposition of B. Varalli-Claypool, D.O., Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Nov. 8, 2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1996		INTENTIONALLY LEFT BLANK					
J1997	11/19/2018	JOM Customer Service Customer Master Data Process	JAN-MS-03121327	JAN-MS-03121359		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1998	12/5/2018	Redline draft of Let's Talk Pain Coalition Website Content	JAN-MS-01241348	JAN-MS-01241348		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1999		INTENTIONALLY LEFT BLANK					
J2000	12/06/2018	Angell M. Opioid Nation. New York Review of Books. December 6, 2018 volume 55, number 19				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2001	12/10/2018	Why Those With Opioid Use Disorder May Not Receive Treatment, Pew Charitable Trusts				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2002	12/10/2018	Alexandra Duncan, Why Those With Opioid Use Disorder May Not Receive Treatment, Pew Charitable Trusts (Dec. 10, 2018),				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2003	12/12/2018	Mexico Attorney General's Office, "Inicia PGR investigación por aseguramiento de laboratorio clandestino en Sinaloa," 23 November 2017. 79 Procuraduría General de la República, "Comunicado PGR 34/18. PGR asegura en la Ciudad de México laboratorio clandestino para elaborar fentanilo," 12 December 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2004		INTENTIONALLY LEFT BLANK					



TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2005	12/12/2018	DUR meeting packet, CoP recommending 100 MME guideline				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2006	12/17/2018	Regulatory Agency Contact Report - 2018-77	JAN-MS-05433750	JAN-MS-05433753		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2007	12/19/2018	Cohen J. Looking Into A Crystal Ball: Some Healthcare Predictions For 2019. Forbes. Dec. 19, 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2008	12/20/2018	U.S. Attorney's Office, US Western District of New York, "Federal Jury Convicts Two Defendants of Narcotics Conspiracy Tied To The El Chapo Mexican Drug Cartel,"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2009	12/21/2018	The State's Expert Witness Disclosures				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2010	12/28/2018	Drug Claim Form				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2011	01/04/2019	Lawrence Scholl, Ph.D., et al., Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017, U.S. Department of Health and Human Services Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report, Vol. 67, Nos. 51 & 52, pp. 1419–1427, January 4, 2019				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2012	01/07/2019	Regulatory Agency Contact Report 2019-002	JAN-MS-03124076	JAN-MS-03124079		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2013	01/17/2019	Deposition of Claire Nguyen, Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Jan. 17, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2014	01/18/2019	Macarena C. Garcia, DrPH, et al., Opioid Prescribing Rates in Nonmetropolitan and Metropolitan Counties Among Primary Care Providers Using an Electronic Health Record System — United States, 2014–2017. Morbidity and Mortality Weekly Report, Volume 68(2);25–30, January 18, 2019.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2015	01/22/2019	Email from Robert Helfrick to Stephanie Dixon	JAN-MS-05433730	JAN-MS-05433730		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2016	01/22/2019	Email from Robert Helfrick to Stephanie Dixon	JAN-MS-05433741	JAN-MS-05433741		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2017	01/23/2019	Cohen, Joshua The Importance of Patient-Centric Opioid Prescribing Guidelines. Forbes. Jan. 23, 2019.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2018	01/24/2019	Deposition of Russell Portnoy, M.D., Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct.)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2019	1/26/2019	[Email] RE: EXTERNAL-Portenoy -- deposition timing	PLTF_2804_0000044	PLTF_2804_000004434		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2020	1/29/2019	Kelly Rolland, Article entitled, "Chronic Pain Patients in need of opioids take anger and frustration to Attorney General's Office, 01/29/2019				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2021	01/30/2019	PPSG website				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2022	1/30/2019	Meg Wingerter, Article entitled, "Confusion over Opioid Prescribing Rules Remains as Legislature Returns," News OK, 01/30/2019				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2023	1/31/2019	Sands, Geneva - "US customs announces largest fentanyl seizure in its history". Available at: <a href="https://www.cnn.com/2019/01/31/health/fentanyl-customs-bn/index.html">https://www.cnn.com/2019/01/31/health/fentanyl-customs-bn/index.html</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2024	01/31/2019	OK Legislation previously cited by Plaintiff, and other legislation researched by Ponder in prep for Colligen's 3213 depo, marked as exhibits.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2025	2/5/2019	Supplemental Exhibit G - James L. Gibson, Ph.D.					
J2026	2/5/2019	Supplemental Exhibit S - Christopher J. Ruhm, Ph.D.					
J2027	02/05/2019	Expert disclosure of James L. Gibson, Ph.D					
J2028	2/7/2019	Opioids and Me, Susan Estrich				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2029		INTENTIONALLY LEFT BLANK					
J2030	02/12/2019	D. Hartung, Buprenorphine Coverage in the Medicare Part D Program for 2007 to 2018, JAMA, 321(6), pp. 607-609, 2019				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2031		INTENTIONALLY LEFT BLANK					
J2032	02/12/2019	Deposition of Shellee Keast, Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Feb. 12, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2033	02/12/2019	Keast S, Kim H, Deyo R, et al. Effects of a prior authorization policy for extended-release/long-acting opioids on utilization and outcomes in a state Medicaid program. Addiction Research Report, Society for the Study of Addiction. Addiction, 113, 1651-1660. Apr. 2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2034	02/12/2019	JAMA Program for 2007 to 2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2035	2/13/2019	Portions of Deposition of S. Crawford, Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct.)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2036	02/19/2019	Deposition of Cindy Hamilton-Fain, Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Feb. 19, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2037		INTENTIONALLY LEFT BLANK					
J2038	02/22/2019	Deposition of M. Herndon, Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Feb. 22, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2039	02/27/2019	Deposition of T. Cothran, Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Feb. 27, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2040	02/28/2019	Deposition of Byron Curtis, Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Feb. 28, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2041		INTENTIONALLY LEFT BLANK					
J2042	03/01/2019	Deposition of Travis Tate, Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Mar. 1, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2043	3/2019	Stanos, Steven P. - "Pain Management with Opioid Analgesics"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2044	03/05/2019	Deposition of K. Egesdal, D.Ph., Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Mar. 5, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2045	03/06/2019	Deposition of Kerri Wade, Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Mar. 6, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2046	03/06/2019	Deposition of S. Martin, Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Mar. 6, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2047	03/8/2019	Deposition of M. Pohl, M.D., Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct.)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2048	03/12/2019	Andrew Kolodny Tweet, March 12, 2019				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2049	3/12/2019	Andrew Kolodny Re-Tweet, March 12, 2019				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2050	3/13/2019	Janssen Defendants' Expert Disclosure				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2051	03/13/2019	Defendants Johnson & Johnson & Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica, Inc.'s Objections to Topic Nos. 18 and 38 in Plaintiff's Amended Notices of Videotaped 3230(C)(5) Depositions				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2052	3/13/2019	Revised Topic 18 Appendix				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2053	3/14/2019	Zhu, et al., NEJM, Initial Opioid Prescriptions among US Commercially Insured Patients, 2012-2017, New England Journal of Medicine 380:11, pp. 1043-52				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2054	03/15/2019	Szalavitz M. Opioid Addiction Is a Huge Problem, but Pain Prescriptions Are Not the Cause. MIND Guest Blog. Scientific American				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2055	03/19/2019	Deposition of William McAllister, Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Mar. 19, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2056	3/20/2019	Deposition of R. De La Garza, II, Ph.D., Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct.)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2057	03/21/2019	Bebinger, Martha - "Fentanyl-Linked Deaths: The U.S. Opioid Epidemic's Third Wave Begins" (21 Mar. 2019).				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2058	03/22/2019	Deposition of Claire Nguyen, Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct. Mar. 22, 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2059	3/25/2019	OK State Dept. of Health, Document entitled, "Naloxone," OK Web Portal, 2019				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2060	3/26/2019	Deposition of J. Beaman, Oklahoma v. Purdue Pharma LP, No. CJ-2017-816 (Okla. Dist. Ct.)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2061	03/26/2019	FDA Prescription Drug Advertising, Document entitled, "Basics of Drug Ads," 03/26/2019				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2062	3/26/2019	Andrew Kolodny on Twitter, "The Oklahoma Attorney General just announced a \$270 million settlement with Purdue. It's case against JnJ and Teva proceeds full steam ahead," 5 News Texas, 03/26/2019				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2063	3/26/2019	March 26, 2019 Kolodny Tweet (2) "Totally false" re Opioid Settlement money				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2064	4/9/2019	Statement by Douglas Throckmorton, M.D., Deputy Center Director for Regulatory Programs in FDA				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2065	04/09/2019	Statement by Douglas Throckmorton, M.D., Deputy Center Director for Regulatory Programs in FDA's Center for Drug Evaluation and Research, on new opioid analgesic labeling changes to give providers better information for how to properly taper patients who are physically dependent on opioids				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2066	04/24/2019	Kaiser Family Foundation website. State Health Facts: Health Insurance Coverage of the Total Population, available at <a href="http://www.kff.org/other/state-indicator/total-population/?currentTimeframe=0&amp;sortModel=%7B%22colId%22:Location%22,%22asc%22%7D">www.kff.org/other/state-indicator/total-population/?currentTimeframe=0&amp;sortModel=%7B%22colId%22:Location%22,%22asc%22%7D</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2067	04/24/2019	JMCP.org website: Jill Augustine, PharmD, et al., Ability and Use of Comparative Effectiveness Research by P&T Committee Members and Support Staff: A 1-Year Follow-up, <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , Vol. 22, Issue 6, pp. 618-625, June 2016, available at <a href="https://www.jmcp.org/doi/full/10.18553/jmcp.2016.22.6.618">https://www.jmcp.org/doi/full/10.18553/jmcp.2016.22.6.618</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2068	04/24/2019	Medium.com website: Stephen A. Martin, MD, et al., Neat, Plausible, and Generally Wrong: A Response to the CDC Recommendations for Chronic Opioid Use, September 7, 2016, available at <a href="https://medium.com/@stmartin/neat-plausible-and-generally-wrong-a-response-to-the-cdc-recommendations-for-chronic-opioid-use-5c9d9d319f71">https://medium.com/@stmartin/neat-plausible-and-generally-wrong-a-response-to-the-cdc-recommendations-for-chronic-opioid-use-5c9d9d319f71</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2069	04/24/2019	International Anesthesia Research Society website: Frank Brennan, MBBS, et al., The Role of Opioids in Pain Management, <i>Anesthesia &amp; Analgesia</i> , Vol. 105, Issue 6, pp. 1865-1866, available at <a href="https://journals.lww.com/anesthesia-analgesia/fulltext/2007/12000/The_Role_of_Opioids_in_Pain_Management.65.aspx">https://journals.lww.com/anesthesia-analgesia/fulltext/2007/12000/The_Role_of_Opioids_in_Pain_Management.65.aspx</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2070	04/24/2019	American Public Health Association website:				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2071	04/24/2019	Scientific American website: Maia Szalavitz, Opioid Addiction Is a Huge Problem, but Pain Prescriptions Are Not the Cause, <i>Scientific American</i> , May 10, 2016, available at <a href="https://blogs.scientificamerican.com/mind-guest-blog/opioid-addiction-is-a-huge-problem-but-pain-prescriptions-are-not-the-cause/">https://blogs.scientificamerican.com/mind-guest-blog/opioid-addiction-is-a-huge-problem-but-pain-prescriptions-are-not-the-cause/</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2072	04/24/2019	SAMHSA website: Results from the 2014 National Survey on Drug Use and Health: Detailed Tables, U.S. Department of Health and Human Services, Substance Abuse and Mental Health Service Administrations, available at <a href="https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs2014/NSDUH-DetTabs2014.htm#tab6-47b">https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs2014/NSDUH-DetTabs2014.htm#tab6-47b</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2073	04/24/2019	SAMHSA website: Pradip K. Muhuri, et al., Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States, <i>Substance Abuse and Mental Health Services Administration</i> , August 2013, available at <a href="https://www.samhsa.gov/data/sites/default/files/DR006/DR006/nonmedical-pain-reliever-use-2013.htm">https://www.samhsa.gov/data/sites/default/files/DR006/DR006/nonmedical-pain-reliever-use-2013.htm</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2074	04/24/2019	Castlighthealth.com website: Glenwood Barbee, Breaking Down Opioid Abuse Trends in America's Workforce, April 20, 2016, available at <a href="https://www.castlighthealth.com/2016/04/20/the-opioid-crisis-in-americas-workforce/">https://www.castlighthealth.com/2016/04/20/the-opioid-crisis-in-americas-workforce/</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2075	04/24/2019	BabyCenter.com website: About BabyCenter, LLC, available at <a href="http://www.babycenter.com/about">www.babycenter.com/about</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2076	04/24/2019	Babycenter.com website: Editorial and Advertising Policy, available at <a href="http://www.babycenter.com/editorial-advertising-policy">www.babycenter.com/editorial-advertising-policy</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2077	04/24/2019	Babycenter.com website: BabyCenter Medical Advisory Board, available at <a href="http://www.babycenter.com/prkit-advisoryboard">www.babycenter.com/prkit-advisoryboard</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2078	04/24/2019	Babycenter.com website: What Are Opioids?, available at <a href="http://www.babycenter.com/0_what-are-opioids_20004416.bc">www.babycenter.com/0_what-are-opioids_20004416.bc</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2079	04/24/2019	Babycenter.com website: Chart: Which medicines contain opioids?, available at <a href="http://www.babycenter.com/0_chart-which-medicines-contain-opioids_20000902.bc">www.babycenter.com/0_chart-which-medicines-contain-opioids_20000902.bc</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2080	04/24/2019	Babycenter.com website: Is it safe to take opioids during pregnancy?, available at <a href="http://www.babycenter.com/0_is-it-safe-to-take-opioids-during-pregnancy_20004418.bc">www.babycenter.com/0_is-it-safe-to-take-opioids-during-pregnancy_20004418.bc</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2081	04/24/2019	Babycenter.com website: Is it safe to take opioids while breastfeeding?, available at <a href="http://www.babycenter.com/0_is-it-safe-to-take-opioids-while-breastfeeding_20004424.bc">www.babycenter.com/0_is-it-safe-to-take-opioids-while-breastfeeding_20004424.bc</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2082	04/24/2019	Babycenter.com website: Is it safe to take opioids during labor?, available at <a href="http://www.babycenter.com/0_is-it-safe-to-take-opioids-during-labor_20004422.bc">www.babycenter.com/0_is-it-safe-to-take-opioids-during-labor_20004422.bc</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2083	04/24/2019	Babycenter.com website: What is my risk of becoming addicted if I take opioids?, available at <a href="http://www.babycenter.com/0_what-is-my-risk-of-becoming-addicted-if-i-take-opioids_20004430.bc">www.babycenter.com/0_what-is-my-risk-of-becoming-addicted-if-i-take-opioids_20004430.bc</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2084	04/24/2019	Babycenter.com website: How can I minimize my risk of addiction when I'm taking opioids?, available at <a href="http://www.babycenter.com/0_how-can-i-minimize-my-risk-of-addiction-when-im-taking-opioids_20004432.bc">www.babycenter.com/0_how-can-i-minimize-my-risk-of-addiction-when-im-taking-opioids_20004432.bc</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2085	04/24/2019	Babycenter.com website: What are the signs that someone is becoming addicted to opioids?, available at <a href="http://www.babycenter.com/0_what-are-the-signs-that-someone-is-becoming-addicted-to-opioids_20004428.bc">www.babycenter.com/0_what-are-the-signs-that-someone-is-becoming-addicted-to-opioids_20004428.bc</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2086	04/24/2019	FDA website: Approved Risk Evaluation and Mitigation Strategies (REMS). Opioid Analgesic REMS, available at <a href="http://www.accessdata.fda.gov/scripts/cder/remis/index.cfm?event=RemsDetails.page&amp;REMS=17">www.accessdata.fda.gov/scripts/cder/remis/index.cfm?event=RemsDetails.page&amp;REMS=17</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2087	04/25/2019	Castlinghealth.com website: Glenwood Barbee, Breaking down opioid abuse trends in America's workforce, available at <a href="http://www.castlinghealth.com/2016/04/20/the-opioid-crisis-in-americas-workforce/">www.castlinghealth.com/2016/04/20/the-opioid-crisis-in-americas-workforce/</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2088	04/25/2019	FDA website: FDA Opioids Action Plan, U.S. Food and Drug Administration, February 2016, available at <a href="https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm484714.htm">https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm484714.htm</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2089	04/25/2019	CDC website: Deborah Dowell, MD, et al., CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016, Morbidity and Mortality Weekly Report, Centers for Disease Control and Prevention, Vol. 65, No. 1, pp. 1–49, available at <a href="https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm">https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2090	04/25/2019	Clinical Therapeutics website: Joshua P. Cohen, Ph.D., et al., Challenges Involved in the Development and Delivery of Abuse-deterrent Formulations of Opioid Analgesics, Clinical Therapeutics Vol. 40, No. 2, pp. 334 – 344, February 2018, available at <a href="https://www.clinicaltherapeutics.com/article/S0149-2918(18)30004-3/abstract">https://www.clinicaltherapeutics.com/article/S0149-2918(18)30004-3/abstract</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2091	04/25/2019	HHS website: Total US expenditures for opioid pain relievers, by insurance type and year, available at <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955937/figure/F1/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955937/figure/F1/</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2092	04/25/2019	Milliman.com website: Stoddard Davenport, et al., Opioid use disorder in the United States: Diagnosed prevalence by payer, age, sex and state, March 9, 2018, available at <a href="http://www.milliman.com/insight/2018/Opioid-use-disorder-in-the-United-States-Diagnosed-prevalence-by-payer-age-sex-and-state/">http://www.milliman.com/insight/2018/Opioid-use-disorder-in-the-United-States-Diagnosed-prevalence-by-payer-age-sex-and-state/</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2093	04/25/2019	Taylor & Francis website: Louis F. Rossiter, Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US, Journal of Medical Economics, Vol. 17, No. 4, February 24, 2014, available at <a href="https://www.tandfonline.com/doi/full/10.3111/13696998.2014.897628">https://www.tandfonline.com/doi/full/10.3111/13696998.2014.897628</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2094	04/26/2019	Maria A. Dquendo, M.D., et al., Suicide: A Silent Contributor to Opioid-Overdose Deaths, New England Journal of Medicine 378:17, pp. 1567-1569, April 26, 2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2095	04/28/2019	Theresa A. Cassidy, MPH, et al., Changes in Prevalence of Prescription Opioid Abuse after Introduction of an Abuse-Deterrent Opioid Formulation, Pain Medicine, American Academy of Pain Medicine, Vol. 15, pp. 440–451, 2014				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2096	04/28/2019	Nora D. Volkow, MD, et al., Opioid Abuse in Chronic Pain—Misconceptions and Mitigations Strategies, New England Journal of Medicine, Vol. 374, pp. 1253-1263, March 31, 2016				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2097	04/28/2019	Dora H. Lin, MHS, et al., Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers, Journal of the American Medical Association Network Open, Vol. 1, No. 2, pp. 1-13, June 22, 2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2098	04/29/2019	Nurse.com website: Pain Management and Ethics: What's the Right Thing To Do?, available at <a href="http://www.nurse.com/ce/pain-management-and-ethics-what-s-the-right-thing-to-do">www.nurse.com/ce/pain-management-and-ethics-what-s-the-right-thing-to-do</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2099	04/29/2019	Nurse.com website: Chronic Pain: How Do We Treat It in an Era of Increasing Prescription Medication Misuse and Abuse?, available at <a href="http://www.nurse.com/ce/chronic-pain">www.nurse.com/ce/chronic-pain</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2100	04/29/2019	Nurse.com website: Effective Pain Management Is More than Just a Number, available at <a href="http://www.nurse.com/ce/effective-pain-management-is-more-than-just-a-number">www.nurse.com/ce/effective-pain-management-is-more-than-just-a-number</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2101	04/29/2019	Nurse.com website: Substance Abuse: Helping Women and Their Children, available at <a href="http://www.nurse.com/ce/substance-abuse-helping-women-and-their-children">www.nurse.com/ce/substance-abuse-helping-women-and-their-children</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2102	04/29/2019	Nurse.com website: Medication Nonadherence: America's Other Drug Problem, available at <a href="http://www.nurse.com/ce/medication-nonadherence">www.nurse.com/ce/medication-nonadherence</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2103	04/29/2019	Nurse.com website: Knocking Out Pain Safely with PCA, available at <a href="http://www.nurse.com/ce/knocking-out-pain-safely-with-pca">www.nurse.com/ce/knocking-out-pain-safely-with-pca</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2104	04/29/2019	Nurse.com website: Recognizing Drug-Seeking Behavior, available at <a href="http://www.nurse.com/ce/recognizing-drugseeking-behavior">www.nurse.com/ce/recognizing-drugseeking-behavior</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2105	04/29/2019	Nurse.com website: Evidence-Based Approaches to Pain Control, available at <a href="http://www.nurse.com/ce/evidence-based-approaches-to-pain-control">www.nurse.com/ce/evidence-based-approaches-to-pain-control</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2106	04/29/2019	Nurse.com website: Motivational Interviewing, available at <a href="http://www.nurse.com/ce/motivational-interviewing">www.nurse.com/ce/motivational-interviewing</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2107	05/2017	Oklahoma State Department of Health Enhanced State Opioid Overdose Surveillance (ESOOS) State Call: 11/30/16 Document	OSDH-01289446	OSDH-01289516		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2108	07/2018	Oklahoma State Department of Health Alert Network Health Update Document	OSDH-00472202	OSDH-00472205		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2109	07/2018	Oklahoma State Department of Health Alert Network Health Update Document	OSDH-00700883	OSDH-00700886		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2110	07/2018	Document from Oklahoma State Department of Health	OSDH-01542999	OSDH-01543002		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2111	07/2018	Document from Oklahoma State Department of Health	OSDH-01550511	OSDH-01550514		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2112	07/2018	Document from Oklahoma State Department of Health	OSDH-01555713	OSDH-01555716		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2113	8/9/2019	U.S. Attorney's Office, US Western District of New York, "17 Defendants Indicted In International Drug Trafficking Ring."				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	



TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2114	09/19/2019	InSightCrime. Colombia Production Breaks New Record Levels: UNODC Report. Parker Asmann. September 19, 2019.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2115	2002	ÓACCME Standards for Commercial Support of Continuing Medical EducationÓ Presentation	JAN-MS-04211271	JAN-MS-04211271		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2116	2002	DRAFT PR - Questions and Answers - Potential for Misuse DURAGESIC	JAN-MS-00781333	JAN-MS-00781333		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2117		Bates numbered documents related to James Gibson work product, State of Oklahoma, ex rel., Mike Hunter, Attorney General of Oklahoma v. Purdue Pharma L.P., et al., District Court of Cleveland County, State of Oklahoma, CJ-2017-816	OKEXPERT-00000005	OKEXPERT-00000017			
J2118		Bates numbered documents related to James Gibson work product, State of Oklahoma, ex rel., Mike Hunter, Attorney General of Oklahoma v. Purdue Pharma L.P., et al., District Court of Cleveland County, State of Oklahoma, CJ-2017-816	OKEXPERT-00018711	OKEXPERT-00018714			
J2119		Bates numbered documents related to James Gibson work product, State of Oklahoma, ex rel., Mike Hunter, Attorney General of Oklahoma v. Purdue Pharma L.P., et al., District Court of Cleveland County, State of Oklahoma, CJ-2017-816	OKEXPERT00018717	OKEXPERT00018760			
J2120		Bates numbered documents related to Oklahoma Attorney General Statistical Sample (OKAGSS) data, State of Oklahoma, ex rel., Mike Hunter, Attorney General of Oklahoma v. Purdue Pharma L.P., et al., District Court of Cleveland County, State of Oklahoma, CJ-2017-816	OKAGSS_00000001	OKAGSS_00327689		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2121		Bates numbered documents related to Oklahoma HealthChoice Prescriptions and Medical Claims, State of Oklahoma, ex rel., Mike Hunter, Attorney General of Oklahoma v. Purdue Pharma L.P., et al., District Court of Cleveland County, State of Oklahoma, CJ-2017-816	EGID-00000141	EGID-00000204		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2122		Bates numbered documents related to Oklahoma Medicaid prescriptions, State of Oklahoma, ex rel., Mike Hunter, Attorney General of Oklahoma v. Purdue Pharma L.P., et al., District Court of Cleveland County, State of Oklahoma, CJ-2017-816:	OHCA-00000001	OHCA-00000002		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2123		Bates numbered documents related to Oklahoma Medicaid prescriptions, State of Oklahoma, ex rel., Mike Hunter, Attorney General of Oklahoma v. Purdue Pharma L.P., et al., District Court of Cleveland County, State of Oklahoma, CJ-2017-816:	OHCA-00445496	OHCA-00445503		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2124		Bates numbered documents related to Oklahoma Medicaid prescriptions, State of Oklahoma, ex rel., Mike Hunter, Attorney General of Oklahoma v. Purdue Pharma L.P., et al., District Court of Cleveland County, State of Oklahoma, CJ-2017-816:	OHCA-00445507	OHCA-00445508		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2125		Bates numbered documents related to Oklahoma Medicaid prescriptions, State of Oklahoma, ex rel., Mike Hunter, Attorney General of Oklahoma v. Purdue Pharma L.P., et al., District Court of Cleveland County, State of Oklahoma, CJ-2017-816:	OHCA-00445512	OHCA-00445535		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2126		Bates numbered documents related to Oklahoma Medical Examiner data, State of Oklahoma, ex rel., Mike Hunter, Attorney General of Oklahoma v. Purdue Pharma L.P., et al., District Court of Cleveland County, State of Oklahoma, CJ-2017-816	OCME-00000812	OCME-00000812		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2127		Bates numbered documents related to Oklahoma Treatment Episode Data Set (TEDS) and Okla. Dept. of Mental Health and Substance Abuse Services (ODMHSAS) Online Query System (OOOnQueS) data, State of Oklahoma, ex rel., Mike Hunter, Attorney General of Oklahoma v. Purdue Pharma L.P., et al., District Court of Cleveland County, State of Oklahoma, CJ-2017-816:	ODMHSAS-00000273	ODMHSAS-00000276		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2128		Bates numbered documents related to Oklahoma Treatment Episode Data Set (TEDS) and Okla. Dept. of Mental Health and Substance Abuse Services (ODMHSAS) Online Query System (OOnQueS) data, State of Oklahoma, ex rel., Mike Hunter, Attorney General of Oklahoma v. Purdue Pharma L.P., et al., District Court of Cleveland County, State of Oklahoma, CI-2017-816:	ODMHSAS-00037875	ODMHSAS-00037884		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2129		Bates numbered documents related to Oklahoma Treatment Episode Data Set (TEDS) and Okla. Dept. of Mental Health and Substance Abuse Services (ODMHSAS) Online Query System (OOnQueS) data, State of Oklahoma, ex rel., Mike Hunter, Attorney General of Oklahoma v. Purdue Pharma L.P., et al., District Court of Cleveland County, State of Oklahoma, CI-2017-816:	ODMHSAS-00038070	ODMHSAS-00038070		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2130		ASPMN Mission Statement & Goals				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2131		ASPMN Formation & Early History				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2132		US Pain Foundation About Us				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2133		Cancer Action Network About page				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2134		Cancer Action Network Corporate Members page				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2135		Cancer Action Network Pain Relief page				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2136		Smart Moves, Smart Choices Poster				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2137		Opioid Risk Tool				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2138		Nucynta ER Package Insert	JAN-MS-00229100	JAN-MS-00229100		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2139		[Spreadsheet] NPEC 2003 Faculty honoraria budget proposal	JAN-MS-00314815			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2140		[Spreadsheet] Duragesic Defend and Grow results	JAN-MS-00370029			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2141		[Spreadsheet] National Advocacy Opportunities	JAN-MS-00399854			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2142		[Spreadsheet] National Advocacy Opportunities	JAN-MS-00399865			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2143		[Spreadsheet] National Advocacy Opportunities	JAN-MS-00399866			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2144		[Spreadsheet] Speaker Honoraria Details	JAN-MS-00426175			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2145		[Attachment] Budget for grant	JAN-OK-00147881			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2146		July Sales IMPACT Pull-Through Guide, Learning and Exploring with you PCP and Specialists	JAN-MS-00091517			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2147		[Presentation] Training Workshops, Nucynta and Nucynta ER	JAN-MS-00091555			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2148		Extended-Release and Long-Acting Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS) Supporting Document	JAN-MS-00935481	JAN-MS-00935534		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2149	1983	Wong-Baker FACES Pain Rating Scale (1983)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2150	1988	Kevin Healy, "Coca, the State and the Peasantry in Bolivia," in Bruce Bagley, Bruce, ed. Assessing the America's War on Drugs, Special issue Journal of InterAmerican Studies and World Affairs (JISWA), Vol. 30, Nos. 2 & 3, (Summer/Fall 1988) pp. 105-126.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2151	1988	T. Rudy, "Chronic Pain and Depression: Toward a Cognitive-Behavioral Mediation Model," 35 Pain 129 (1988)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2152	1989	Bruce Michael Bagley, Bruce, "The New Hundred Years War?: U.S. National security and the War on Drugs in Latin America," in Donald J. Mabry, ed., The Latin American Narcotics Trade and U.S. National Security. New York: Greenwood Press, Contributions in Political Science, Number 240, 1989, pp. 43-58				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2153	1993	M. Roland, "A Study of the Natural History of Back Pain: Part I: Development of a Reliable and Sensitive Measure of Disability in Low-Back Pain," 8 Spine 141 (1983)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2154	1994	M. Geisser, "Catastrophizing, Depression and the Sensory, Affective and Evaluative Aspects of Chronic Pain," 59 Pain 79 (1994)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2155	1997	The Use of Opioids for the Treatment of Chronic Pain. A Consensus Statement from the American Academy of Pain Medicine and the American Pain Society, The Clinical Journal of Pain, Vol. 13, No. 1, pp. 6-8, 1997				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2156	1998	M. Pappagallo, "The Concept of Pseudotolerance to Opioids," Journal of Pharmaceutical Care in Pain & Symptom Control (1998)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2157	1998	Opioid tolerance: the clinical perspective, B-J Collett				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2158	1998	British Journal of Anaesthesia Opioid tolerance: the clinical perspective, B-J Collett				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2159	1999	David F. Musto, The American Disease: Origins of Narcotics Control (New Haven: Yale U. Press, 1999), pp. 1-244.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2160	2000	David Musto, ed., One Hundred Years of Heroin. Westport, Conn.: Auburn House, 2000, 236 p.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2161	2000	M. Costigan, "Pain: Molecular Mechanisms," 1 The Journal of Pain (Supp. 1) 35 (Fall 2000)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2162	2001	[Word Doc] 2001 Product Business Plan Summary	JAN-MS-02992128	JAN-MS-02992130		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2163	2001	M. Nugent, "Long-Term Observations of Patients Receiving Transdermal Fentanyl After a Randomized Trial," 21 Journal of Pain & Symptom Management 385 (2001)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2164	2001	National Pharmaceutical Council, Pain: Current Understanding of, Assessment, Management, and Treatments (2001)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2165	2001	NIDA, Diagnosis and Treatment of Drug Abuse in Family Practice: Treatment, (2001)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2166	2002	Fishbain, David - "Medico-legal Rounds: Medico-legal Issues and Breaches of 'Standards of Medical Care' in Opioid Tapering for Alleged Opioid Addiction"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2167	2002	[Spreadsheet] Duragesic Team Status Report - Active Promotional Programs 2002	JAN-MS-00312933	JAN-MS-00312945		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2168	2003	Elander, James - "Pain Management and Symptoms of Substance Dependence Among Patients with Sickle Cell Disease" (2003)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2169	2003	Pain Assessment and Documentation Tool from OKHCA Pain Management Toolkit				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2170	2003	Pain Assessment and Documentation Tool and Guidebook				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2171	2003	Thomas S. Rector, Ph.D., et al., Effect of Tiered Prescription Copayments on the Use of Preferred Brand Medications, <i>Medical Care</i> , Vol. 41 No. 3, pp. 398-406, 2003				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2172	2003	M. Balr, "Depression and Pain Comorbidity: A Literature Review," 163 Arch Intern Med 2433 (2003)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2173	2003	M. Tsuda, "Letters: P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury," 424 Nature 779 (2003)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2174	2004	SUPP 7, A New Tool to Assess and Document Pain Outcomes in Chronic Pain Patients Receiving Opioid Therapy, Steven Passik and others	JAN-MS-02312280	JAN-MS-02312289		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2175	2004	Michael K. Steinberg, Joseph J. Hobbs and Kent Mathewson, eds., Dangerous Harvest: Drug Plants and the Transformation of Indigenous Landscapes (2004)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2176	2004	Cohen J. Are clinical practice guidelines impartial? <i>International Journal of Technology Assessment in Health Care</i> , 20:4 (2004), 415-420.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2177	2004	Steven D. Passik, Ph.D., et al., A New Tool to Assess and Document Pain Outcomes in Chronic Pain Patients Receiving Opioid Therapy, <i>Clinical Therapeutics</i> , Vol. 26, No. 4, pp. 552-561, 2004				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2178	2004	Manchanda, Puneet et al., Responsiveness of Physician Prescription Behavior to Salesforce Effort: An Individual Level Analysis, <i>Marketing Letters</i> , 15:2-3, pp. 129-145, 2004				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2179	2004	T.J. Gan, "Patient Preferences for Acute Pain Treatment," 92 <i>British Journal of Anesthesia</i> 681 (2004)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2180	2005	SUPP 8, An observational study of health-related quality of life and pain outcomes in chronic low back pain patients treated with fentanyl transdermal system, Mark Kosinski and others				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2181	2005	An observational study of health-related quality of life and pain outcomes in chronic low back pain patients treated with fentanyl transdermal system, Mark Kosinski and others				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2182	2006	Lusher, Joanne - "Analgesic Addiction and Pseudoaddiction in Painful Chronic Illness" (Mar./April 2006)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2183	2006	Passik, Steven D. - "An Opioid Screen Instrument: Long-Term Evaluation of the Utility of the Pain Medication Questionnaire by Holmes et al." (2006)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2184	2006	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00291441	JAN-MS-00291441		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2185	2006	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00291443	JAN-MS-00291443		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2186	2006	Appendix FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00291444	JAN-MS-00291444		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2187	2006	Appendix FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00291445	JAN-MS-00291445		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2188	2006	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00291446	JAN-MS-00291446		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2189	2006	Appendix FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00291447	JAN-MS-00291447		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2190	2006	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00291448	JAN-MS-00291448		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2191	2006	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00291449	JAN-MS-00291449		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2192	2006	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00291450	JAN-MS-00291450		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2193	2006	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00291451	JAN-MS-00291451		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2194	2006	2006 SOM Algorithm Validation Documents Cover Page	JAN-MS-05444824	JAN-MS-05446674		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2195	2006	National Center for Health Statistics, HHS, Health, United States (2006)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2196	2006	X. Jin, "Acute p38-Mediated Modulation of Tetrodotoxin-Resistant Sodium Channels in Mouse Sensory Neurons by Tumor Necrosis Factor" 26 Journal of Neuroscience 246 (2006)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2197	2007	Fleming, Michael F. - "Substance Use Disorders in a Primary Care Sample Receiving Daily Opioid Therapy" (2007)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2198	2007	Janssen Periodic Safety Update Report- Duragesic	JAN-MS-00213787	JAN-MS-00213787		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2199	2007	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213788	JAN-MS-00213788		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2200	2007	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213789	JAN-MS-00213789		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2201	2007	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213790	JAN-MS-00213790		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2202	2007	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213791	JAN-MS-00213791		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2203	2007	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213792	JAN-MS-00213792		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2204	2007	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213793	JAN-MS-00213793		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2205	2007	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213794	JAN-MS-00213794		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2206	2007	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213796	JAN-MS-00213796		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2207	2007	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213797	JAN-MS-00213797		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2208	2007	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213798	JAN-MS-00213798		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2209	2007	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213799	JAN-MS-00213799		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2210	2007	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213800	JAN-MS-00213800		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2211	2007	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213801	JAN-MS-00213801		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2212	2007	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213802	JAN-MS-00213802		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2213	2007	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213803	JAN-MS-00213803		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2214	2007	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213804	JAN-MS-00213804		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2215	2007	Appendix FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213805	JAN-MS-00213805		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2216	2007	Appendix FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213806	JAN-MS-00213806		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2217	2007	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213807	JAN-MS-00213807		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2218	2007	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213808	JAN-MS-00213808		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2219	2007	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213809	JAN-MS-00213809		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2220	2007	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213810	JAN-MS-00213810		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2221	2007	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213811	JAN-MS-00213811		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2222	2007	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213812	JAN-MS-00213812		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2223	2007	M. Fleming, "Substance Use Disorders in a Primary Care Sample Receiving Daily Opioid Therapy," Journal of Pain Medicine (2007)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2224	2007	M. Hutchinson, "Opioid-Induced Glial Activation: Mechanisms of Activation and Implications for Opioid Analgesia, Dependence, and Reward," 7 Scientific World Journal 98 (2007)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2225	2007	N. Katz, "Challenges in the Development of Prescription Opioid Abuse-Deterrent Formulations," 23 Clinical Journal of Pain 648 (2007)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	



TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2226	2008	American Society of Health-System Pharmacists. ASHP guidelines on the pharmacy and therapeutics committee and the formulary system. Am J Health-Syst Pharm. 2008; 65:1272-83				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2227	2008	Fishbain, David A. - "What Percentage of Chronic Nonmalignant Pain Patients Exposed to Chronic Opioid Analgesic Therapy Develop Abuse/Addiction and/or Aberrant Drug-Related Behaviors? A Structured Evidence-Based Review" (2008)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2228	2008	[PDF] EXHIBIT B - WORK ORDER TEMPLATE (B1) TO BE USED WHEN QUOTING AND SUBMITTING PROJECT ESTIMATES and CHANGE ORDERS (B2) TO THE CLIENT PRICING IN ACCORDANCE WITH RATE CARD (B3)	JAN-MS-00328672	JAN-MS-00328675		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2229	2008	M. Fagan, "Do Internal Medicine Residents Find Pain Medication Agreements Useful?" 24 Clinical Journal of Pain 35 (2008)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2230	2008	M. Kunz, "The Relation Between Catastrophizing and Facial Responsiveness to Pain," 140 Pain 127 (2008)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2231	2008	U. Coffeen, "Dopamine receptors in the anterior insular cortex modulate long-term nociception in the rat," 12 European Journal of Pain 535 (2008)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2232	2008	V. Rollason, "Pharmacogenetics of Analgesics: Toward the Individualization of Prescription," 9 Pharmacogenetics 905 (2008)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2233	2009	"Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study, Martin Hale	JAN-MS-00092193	JAN-MS-00092202		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2234	2009	Duragesic Seventh Risk Management Plan Progress Report	JAN-MS-00165622	JAN-MS-00165622		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2235	2009	A.G., Schaefer, B. Bahney, and K. J. Riley, Security in Mexico: Implications for U.S. policy Options. Santa Monica California: Rand Corporation, 2009.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2236	2009	Paul Gootenberg "Talking About the Flow: Drugs, Borders, and the Discourse of Drug Control," Cultural Critique, 71, Winter 2009, 13-49.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2237	2009	Peter Andreas, Border Games: Policing the U.S.-Mexican Divide. Cornell, 2nd edition, 2009.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2238	2009	2009 Incentive Compensation and Recognition Plan: PriCara Pain Representative-Q3 Update	JAN-MS-00589612	JAN-MS-00589622		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2239	2009	Finding Relief Brochure	JAN-MS-00829879	JAN-MS-00829899		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2240	2009	Nucynta eRep assets	JAN-MS-04183671	JAN-MS-04183740		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2241	2009	Efficacy and Tolerability of Tapentadol Immediate Release and Oxycodone HCl Immediate Release in Patients Awaiting Primary Joint Replacement Surgery for End-Stage Joint Disease: A 10-Day, Phase III, Randomized, Double-Blind, Active- and Placebo-Controlled Study, Craig Hartrick	JAN-MS-00092226			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2242	2009	Kurt Kroenke, MD, et al., Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews, General Hospital Psychiatry, Vol. 31, pp. 206-219, 2009				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2243	2009	M. Etropolski, "Efficacy and Safety of Tapentadol Extended Release Versus Oxycodone Controlled Release in Opioid-Naïve and Opioid-Experienced Patients with Chronic Pain Associated with Osteoarthritis of the Knee," 17 Osteoarthritis and Cartilage S175 (2009)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2244	2009	Nucynta Savings Card (02TL09194A) (2009)	JAN-MS-00236318			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2245	2009	Nucynta Savings Card and coupon (02TL09194B) (2009)	JAN-MS-00236319			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2246	2010	Noble M. - "Long-term opioid management for chronic noncancer pain (Review)" (2010)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2247	2010	Marc Fischer, et al., Patient- or Physician-Oriented Marketing: What Drives Primary Demand for Prescription Drugs?, Journal of Marketing Research, Vol. 47, pp. 103-121, 2010				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2248	2010	Washington Agency Medical Directors' Group, Interagency Guideline on Opioid Dosing for Chronic Non-Cancer Pain: An Educational Aid to Improve Care and Safety with Opioid Therapy (2010)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2249	2010	Washington Department of Labor and Industries, Opioid Progress Report Chronic, Non-Cancer Pain (2010)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2250	2010	WebMD-Nucynta Alert Email (02TL10031) (2010)	JAN-MS-00236004			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2251	2010	Oklahoma Health Improvement Plan 2010-2014, Oklahoma State Department of Health				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2252	2011	Peter Chalk, The Latin American Drug Trade: Scope, Dimensions, Impact and Response. Santa Monica, CA: Rand Corporation, Prepared for the United States Air Force, 2011, 87 p.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2253	2011	Passik, Steven D. - "Pseudoaddiction revisited: a commentary on clinical and historical considerations" (2011)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2254	2011	National Academies of Science, Engineering & Medicine, <i>Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research</i> (2011)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2255	2012	2012 Incentive Compensation and Recognition Plan	JAN-MS-00089006	JAN-MS-00089037		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2256	2012	Bruce Bagley, Bruce, "Drug Trafficking and Organized Crime in Latin America: Major Trends in the 21st Century." Washington, D.C: Latin American Program, Woodrow Wilson Center, 2012, 36 p.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2257	2012	Minozzi, Silvia - "Development of dependence following treatment with opioid analgesics for pain relief: a systematic review" (2012)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2258	2012	[Word Doc] 2012 Performance Planning & Review	JAN-MS-00790365	JAN-MS-00790372		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2259	2012	[Report] Totality Form RFP for Vendor Contract: Nucynta Prescribing Practice Ad Board	JAN-MS-01453488	JAN-MS-01453491		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2260	2013	Pain Physician Journal: Efficacy of Tapentadol ER for Managing Moderate to Severe Chronic Pain, Marc Afialo et al.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2261	2013	Cohen J, Wilson A, Manzojillo K. Clinical and economic challenges facing pharmacogenomics. <i>The Pharmacogenomics Journal</i> (2013) 13, 378-388.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2262	2013	Muhuri, Pradip K. - "Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States" (2013)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2263	2013	Proctor, Steven L. - "Prevalence of Substance Use and Psychiatric Disorders in a Highly Select Chronic Pain Population" (Jan./Feb. 2013)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2264	2013	Woodcock, Janet - Response to Physicians for Responsible Opioid Prescribing (2013)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2265	2013	Powerful Chronic and Acute Pain Management - Nucynta ER, Nucynta	JAN-MS-00229356			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2266	2013	Internal Medicine PAIN Sales Force 1st Quarter 2013 Call Plan	JAN-MS-02979844	JAN-MS-02979845		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2267	2013	Pain Physician Journal: Efficacy of Tapentadol ER for Managing Moderate to Severe Chronic Pain, Marc Afialo et al.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2268	2013	M. Afialo, "Efficacy of Tapentadol ER for Managing Moderate to Severe Chronic Pain," 16 Pain Physician 27 (2013)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2269	2013	M. Soledad Cepeda, "Comparison of Opioid Doctor Shopping for Tapentadol and Oxycodone: A Cohort Study," 14 Journal of Pain 1227 (2013)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2270	2013	M. Soledad Cepeda, "Comparison of the Risks of Opioid Abuse or Dependence Between Tapentadol and Oxycodone: Results From a Cohort Study," 14 Journal of Pain 158 (2013)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2271	2013	M. Vijayaraghavan, "Opioid Analgesic Misuse in a Community-Based Cohort of HIV-Infected Indigent Adults," 173 JAMA Intern Med 236 (2013)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2272	2014	2014 Oklahoma Statutes, Title 63. Public Health and Safety, §63-5030.1. Medicaid Drug Utilization Review Board				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2273	2014	2014 Oklahoma Statutes, Title 63. Public Health and Safety, §63-5030.1. Medicaid Drug Utilization Review Board				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2274	2014	Cassidy T, DasMahapatra P, Black R, Wieman M, Butler S. Changes in Prevalence of Prescription Opioid Abuse after Introduction of an Abuse-Deterrent Opioid Formulation. Pain Medicine 2014; 15:440-451.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2275	2014	Center for Behavioral Health Statistics and Quality (CBHSQ), Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services. Results from the 2014 National Survey on Drug Use and Health: Detailed Tables. 2014.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2276	2014	Cohen J, Felix A. Personalized Medicine's Bottleneck: Diagnostic Test Evidence and Reimbursement. Journal of Personalized Medicine 2014.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2277	2014	Yokell, M. - "Presentation of Prescription and Nonprescription Opioid Overdoses to US Emergency Departments				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2278	2014	Work Order Project: 2014 NUCYNTA/NUCYNTA ER Spear Bureau Vetting	JAN-MS-00990301	JAN-MS-00990304		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2279	2014	JOM SOM Questionnaire in Preparation for On-Site Visit	JAN-MS-02966794	JAN-MS-02966795		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2280	2014	2014 Specialty Pharma Supply Chain Issues & Trends Seminar attendees list	JAN-MS-03124063	JAN-MS-03124063		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2281	2014	M. Etropolski, "Safety and Tolerability of Tapentadol Extended Release in Moderate to Severe Chronic Osteoarthritis or Low Back Pain Management: Pooled Analysis of Randomized Controlled Trials," 31 Adv Ther 604 (2014)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2282	2015	Pain Medicine Wiley Periodicals, Inc.: Tapentadol Abuse Potential: A Postmarketing Evaluation Using a Sample of Individuals Evaluated for Substance Abuse Treatment, Stephen Butler et al.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2283	2015	Pain Medicine Wiley Periodicals, Inc.: Assessing Abuse Potential of New Analgesic Medications Following Market Release: An Evaluation of Internet Discussion of Tapentadol Abuse, Emily McNaughton et al.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2284	2015	Keast S, Nesser N, Farmer K, Strategies aimed at controlling misuse and abuse of opioid prescription medications in a state Medicaid program: a policymaker's perspective, American Journal of Drug and Alcohol Abuse, 41(1), 1-6, 2015				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2285	2015	RADARS -				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2286	2015	Jones, Christopher M. - "Vital Signs: Demographic and Substance Use Trends Among Heroin Users—United States, 2002-2013 (2015)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2287	2015	Mowbray, Orion - "Prescription pain reliever misuse prevalence, correlates, and origin of possession throughout the life course" (2015)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2288	2015	Tapentadol Abuse Potential: A Postmarketing Evaluation Using a Sample of Individuals Evaluated for Substance Abuse by Stephen F. Butler, Emily C. McNaughton, MPH and Ryan A. Black, PhD				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2289	2015	Pain Medicine Wiley Periodicals, Inc.: Assessing Abuse Potential of New Analgesic Medications Following Market Release: An Evaluation of Internet Discussion of Tapentadol Abuse, Emily McNaughton et al.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2290	2015	State-by-state reimbursement status advertisements (022292-140930AL-WY) (2015)	JAN-MS-00416816			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2291	2015	Shellie L. Keast, Ph.D., et al., "Strategies aimed at controlling misuse and abuse of opioid prescription medications in a state Medicaid program: a policymaker's perspective, The American Journal of Drug and Alcohol Abuse, 41(1), pp. 1-6, 2015				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2292	2015	Bringing Oklahoma's Health Into Focus - Health OK 2020, Oklahoma Health Improvement Plan, Oklahoma State Department of Health				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2293	2016	Pain Medicine: Diversion and Illicit Sale of Extended Release of Tapentadol in the United States, Richard C. Dart et al.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2294	2016	Frieden T, Houry D. Reducing the Risks of Relief — The CDC's Opioid-Prescribing Guideline. <i>New England Journal of Medicine</i> 2016; 374(16):1501-1504				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2295	2016	<i>Journal of Managed Care &amp; Specialty Pharmacy</i> 2016 22:6: 618-625				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2296	2016	Keast S, Owora A, Nesser N, et al. Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> ; Vol. 22, No. 4; 347-356. Apr.2016				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2297	2016	Zhou C. "Payments For Opioids Shifted Substantially To Public And Private Insurers While Consumer Spending Declined, 1999-2012" <i>Health Affairs (Project Hope)</i> 2016; 35(5):824-831.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2298	2016	Cicero, Theodore J. - "Psychoactive substance use prior to the development of iatrogenic opioid abuse: A descriptive analysis of treatment-seeking opioid abusers"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2299	2016	Campbell, Gabrielle - "Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic noncancer pain: do different measures identify the same patients?" (2016)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2300	2016	MMWR - "CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016" (2016)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2301	2016	NIH - Effective Treatments for Opioid Addiction (2016)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2302	2016	Pain Medicine: Diversion and Illicit Sale of Extended Release of Tapentadol in the United States, Richard C. Dart et al				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2303	2016	N. Volkow, "Opioid Abuse in Chronic Pain—Misconceptions and Mitigation Strategies," 374 <i>N Engl J Med</i> 13 (2016)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2304	2016	T. Lee, "Zero Pain is Not the Goal," 315 <i>JAMA</i> 1575 (2016)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2305	2016	Reducing Prescription Drug Abuse In Oklahoma, A Review of Progress and Updated State Plan				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2306	2017	Kaye A, Jones M, Ripoll J, Jones D, Galan V, Beakley B, Calixto F, Bolden J, Urman R, Manchikanti L, Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse (Part 2), <i>Pain Physician</i> 2017, 20:S111, 2017				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2307	2017	Kaiser Family Foundation. State Health Facts: Health Insurance Coverage of the Total Population. 2017				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2308	2017	Kaiser Family Foundation. States Reporting Medicaid FFS Pharmacy Benefit Management Strategies for Opioids In Place. 2017				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2309	2017	Kaye A, Jones M, Ripoll J, Jones D, Galan V, Beakley B, Calixto F, Bolden J, Urman R, Manchikanti L, Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse (Part 2). Pain Physician 2017; 20:S111-E133				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2310	2017	Keast S, Messer N, Fanner K. Strategies aimed at controlling misuse and abuse of opioid prescription medications in a state Medicaid program: a policymaker's perspective. American Journal of Drug and Alcohol Abuse 2017				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2311	2017	Pezalla, Edmund J. - "Secular trends in opioid prescribing in the USA" (2017)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2312	2017	N. Vadivelu, "Ketorolac, Oxymorphone, Tapentadol, and Tramadol, A Comprehensive Review," 35 Anesthesiology Clin e1 (2017)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2313	2018	Rolling Stones				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2314	2018	US Drug Enforcement Administration, "National Forensic Laboratory Information System: NFLIS-Drug Annual Report 2017," 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2315	2018	US Drug Enforcement Administration, "National Forensic Laboratory Information System: NFLISDrug Annual Report 2017," 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2316	2018	US Drug Enforcement Administration, "National Forensic Laboratory Information System: NFLISDrug Midyear Report 2017," 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2317	2018	US Drug Enforcement Administration, "National Forensic Laboratory Information System: NFLISDrug Midyear Report 2017," 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2318	2018	World Drug Report 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2319	2018	Medicaid Benefits: Prescription Drugs, State Health Facts, Henry J. Kaiser Family Foundation				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2320	2018	CARESOURCE Implements Quantity Limits on Opioids for Ohio Medicaid, 2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2321	2018	Cohen J, Mendoza M, Roland C. Challenges Involved in the Development and Delivery of Abuse-deterrent Formulations of Opioid Analgesics. Clinical Therapeutics 2018; 40(2):334 – 344.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2322	2018	D. Hartung, Buprenorphine Coverage In the Medicare Part D Program for 2007 to 2018. JAMA.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2323	2018	Duragesic Label				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2324	2018	Milliman. Davenport S, Matthews K. 2018. Opioid use disorder in the United States: Diagnosed prevalence by payer, age, sex, and state				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2325	2018	Milliman. Davenport S, Matthews K. 2018. Opioid use disorder in the United States: Diagnosed prevalence by payer, age, sex, and state				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2326	2018	"Editorial: Pain, Opioids, and Suicide Mortality in the United States," Annals of Internal Medicine				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2327	2018	Ashburn, Michael A. - "Increasing Evidence for the Limited Role of Opioids to Treat Chronic Noncancer Pain" (2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2328	2018	Busse, Jason W. - "Opioids for Chronic Noncancer Pain (A Systematic Review and Meta-analysis)" (2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2329	2018	Hedegaard, Holly - "Drugs Most Frequently Involved in Drug Overdose Deaths: United States, 2011-2016" (2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2330	2018	Jalal, Hawre - "Changing Dynamics of drug overdose epidemic in the United States from 1979 through 2016" (2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2331	2018	Karamitros, T. - "Human Endogenous Retrovirus-K HML-2integration within RASGRF2 is associated with intravenous drug abuse and modulates transcription in a cell-line model" (2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2332	2018	Voelker, Rebecca - "States Move to Substitute Opioids With Medical Marijuana to Quell Epidemic" (2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	



TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2333	2019	Mexico Cartels Forecast 2019				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2334	2019	Hartung, Daniel M. - "Buprenorphine Coverage in the Medicare Part D Program for 2007 to 2018"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2335	2019	Chen, Qiushi - "Prevention of Prescription Opioid Misuse and Projected Overdose Deaths in the United States" (2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2336	2019	Chen, Qiushi - "Prevention of Prescription Opioid Misuse and Projected Overdose Deaths in the United States" (2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2337	03/2018	Kacik, A. Blue Cross and Blue Shield Discourages Use of Opioids in Primary Care Treatment. Modern Healthcare. March 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2338	07/12/2017	Post DUR Meeting Notes	OHCA-00085862	OHCA-00085864		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2339	07/2005	Draft Response to July 29, 2005 FDA letter received on IONSYS RiskMAP		JAN-MS-02136851		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2340	01/2005	Suchin Virabhak, POH.D., et al., Physicians' Prescribing Responses to a Restricted Formulary: The Impact of Medicaid Preferred Drug Lists in Illinois and Louisiana, The American Journal of Managed Care, SP14-SP20, January 2005				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2341	01/2006	Policy on Sales Representative Interactions with Health Care Professionals (OMIPS HCC)	JAN-MS-02400273	JAN-MS-02400239		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2342	01/2006	OMIPS Health Care Compliance Reference Guide	JAN-MS-02508522	JAN-MS-02508805		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2343	01/2012	[Spreadsheet] Nucynta Roles - Staffing Scenarios	JAN-MS-00775845	JAN-MS-00775847		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2344	01/2019	National Institute on Drug Abuse. Overdose Death Rates. January, 2019.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2345	02/1996	Berndt, Ernst R. The Practice of Econometrics: Classic and Contemporary, Massachusetts Institute of technology and the National Bureau of Economic Research,				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2346	02/2000	CVS caremark card - Ohio	JAN-MS-00867324	JAN-MS-00867325		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2347	02/2004	Elander, James - "Understanding the Causes of Problematic Pain Management in Sickle Cell Disease: Evidence that Pseudoaddiction Plays a More Important Role than Genuine Analgesic Dependence" (Feb. 2004)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2348	02/2005	Dear Doctor letter	JAN-MS-00780903	JAN-MS-00780903		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2349	02/2005	Dear Doctor letter from Janssen to Healthcare Professional	JAN-MS-00780903	JAN-MS-00780904		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2350	02/2006	[Powerpoint] Prescribing Decisions for Short-Acting Opioids	JAN-MS-00435726			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2351	02/2010	[Form] Pain Care Form 2010 Meetings Schedule	JAN-MS-00922357	JAN-MS-00922368		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2352	02/2013	Nucynta ER - Powerful Pain Management: Proven across multiple acute and chronic pain models	JAN-MS-00229171			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2353	02/2014	What America's Users Spend on Illegal Drugs: 2000-2010, Prepared by RAND Corporation for the Office of National Drug Control Policy.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2354	02/2016	Centers for Disease Control and Prevention. Dowell D, Haegerich T, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain — United States. MMWR Food and Drug Administration. FDA Opioids Action Plan. February 2016				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2355	02/2016	Food and Drug Administration. FDA Opioids Action Plan. February 2016				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2356	02/2016	Ensuring Access to Pain Care, American Academy of Pain Medicine, 32nd Annual Meeting, 2016				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2357	02/2017	Joji Suzuki and Saria El-Haddad, "A review: Fentanyl and non-pharmaceutical fentanyls," Drug and Alcohol Dependence, Vol. 171 (February 2017), pp. 107-116.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2358	02/2018	Szalavitz M. The Feds Are About to Stick it to Pain Patients in a Big Way. Vice				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2359	03/1991	Duragesic Journal Advertising Overview March 1991 - Present	JAN-MS-00305469			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2360	03/1998	Gajraj, Noor - "Opiate Abuse or Undertreatment?"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2361	03/2010	Boscarino, Joseph A. - "Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system" (March 2010)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2362	03/2013	[Presentation] CNS Pain Team Q2-Q4 Call Plan Strategy	JAN-MS-02734353	JAN-MS-02734357		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2363	03/2014	US Department of State, Bureau of International Narcotics and Law Enforcement Affairs, "2014 International Narcotics Control Strategy Report (INCSR)," March 2014				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2364	03/2015	[Nucynta and Nucynta ER] State Reimbursement Statuses	JAN-MS-00416816	JAN-MS-00416899		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2365	03/2017	House of Representatives Committee on Energy and Commerce, Subcommittee on Oversight and Investigations, "The next wave of the opioid crisis," March 2017.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2366	03/2017	NYPD findings January – March 2017				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2367	03/2018	Centers for Disease Control and Prevention, "Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants - United States, 2015-2016," March 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2368	03/2018	Centers for Disease Control and Prevention, "Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants - United States, 2015-2016," March 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2369	03/2018	Centers for Disease Control and Prevention, "Vital Signs: Trends in Emergency Department Visits for Suspected Opioid Overdoses — United States, July 2016–September 2017", March 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2370	03/2018	NIH - "Opioid Overdose Crisis" (Mar. 2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2371	03/2018	US Department of State: Bureau of International Narcotics and Law Enforcement Affairs, "2018 International Narcotics Control Strategy Report (INCSR)," March 2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2372	03/2018	Throckmorton D. Food and Drug Administration presentation				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2373	03/2019	Stanos, Steven P. - "Pain Management with Opioid Analgesics" (March 2019)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2374	04/2005	Duragesic: Prescribing Information Label Revision (April 2005)	JAN-MS-02392749			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2375	04/2005	Duragesic: Duragesic 12mcg Dosage Frequently Asked Questions (April 2005)	JAN-MS-00314292			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2376	04/2005	Duragesic: Prescribing Information Label Revision Backgrounder and FAQs (April 2005)	JAN-MS-00314356			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2377	04/2006	Elander, James - "Factors Affecting Hospital Staff Judgments About Sickle Cell Disease Pain" (April 2006)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2378	04/2008	Cohen J, Stolk E, Niezen M. Role of Budget Impact in role of bDrug Reimbursement Decisions. Journal of Health Politics, Policy and Law, Vol. 33, No. 2. April 2008.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2379	04/2012	A Different Option for Chronic Pain Management - Nucynta ER	JAN-MS-00229314			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2380	04/2015	Vowles, Kevin E. - "Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data syntheses"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2381	04/2018	Cohen J, Stolk E, Niezen M. Role of Budget Impact in role of Drug Reimbursement Decisions. Journal of Health Politics, Policy and Law, Vol. 33, No. 2. April 2008.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2382	05/2003	[Slide Deck] Neo Pathways Barriers to Effective Pain Management	JAN-MS-02402896	JAN-MS-02402899		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2383	05/2004	The Federation of State Medical Boards of the United States, Inc., Model Guidelines for the Use of Controlled Substances for the Treatment of Pain (May 2004)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2384	05/2006	[Report] R331333 Marketing Definition Research - Final Report	JAN-MS-02358785			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2385	05/2008	[Slide Deck] Neo Pathways Consequences of Undertreatment	JAN-MS-02402900	JAN-MS-02402903		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2386	05/2008	[Slide Deck] Clinical Challenge: Addressing the Limitations of Opioid Analgesics	JAN-MS-02402904	JAN-MS-02402907		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2387	05/2008	[Slide Deck] Undertreatment of Pain: The Evidence is Compelling	JAN-MS-02402908	JAN-MS-02402911		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2388	05/2009	[PDF] Inside the Data	JAN-MS-02214198	JAN-MS-02214206		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2389	05/2010	Nucynta 2010 AI/GI Home Study and Meeting Agendas (May 2010)	JAN-MS-03870226			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2390	05/2014	Amy Lansky, et al., Estimating the Number of Persons Who Inject Drugs in the United States by Meta-Analysis to Calculate National Rates of HIV and Hepatitis C Virus Infections, PLOS ONE Vol. 9, No. 5, p. e97596				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2391	05/2018	Office of the Special Narcotics Prosecutor for the City of New York, "2017 Annual Report," May 2018. Available at: <a href="http://www.snpnyc.org/wp-content/uploads/2018/05/SNP-AR2017.pdf">http://www.snpnyc.org/wp-content/uploads/2018/05/SNP-AR2017.pdf</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2392	05/2018	Audrey J. Weiss, Ph.D., et al., Payers of Opioid-Related Inpatient Stays and Emergency Department Visits Nationally and by State, 2010 and 2015, Healthcare Cost and Utilization Project, May 2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2393	05/2018	Weiss A, Heslin K. Healthcare Cost and Utilization Project Payers of Opioid-Related Inpatient Stays and Emergency Department Visits Nationally and by State, 2010 and 2015.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2394	05/2016	Mark A. Ilgen, et al., Opioid dose and risk of suicide, Pain, May 2016, Vol.157, No. 5, pp. 1079-1084				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2395	06/1990	Peter Reuter and David Rondfeldt, Quest for Integrity: The Mexican-U.S. Drug Problem. Santa Monica, CA: The Rand Corporation, June 1990, 62 p.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2396	06/2005	FDA Periodic Safety Update Reports for Fentanyl	JAN-MS-00291415			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2397	06/2005	FDA Periodic Safety Update Reports for Fentanyl	JAN-MS-00291421			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2398	06/2005	FDA Periodic Safety Update Reports, Initial Reports for Fentanyl	JAN-MS-00291423			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2399	06/2008	Ramkumar Janakiraman, et al., Physicians' Persistence and Its Implications for Their Response to Promotion of Prescription Drugs, Management Science, Vol. 54, No. 6, pp. 1080-1093, June 2008				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2400	06/2018	National Institute on Drug Abuse. What is heroin, Revised on June 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2401	07/2001	Fusun Gönül, et al., Promotion of Prescription Drugs and Its Impact on Physicians' Choice Behavior, Journal of Marketing, Vol. 65, No. 3, pp. 79-90, July 2001				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2402	07/2011	Copy of 2011 Get Smart, Take Action Teen Prescription Drug Abuse Awareness School Tool Kit	JAN-MS-00835579	JAN-MS-00835618		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2403	07/2016	Commission on Security and Cooperation in Europe: US Helsinki Commission, "The Opioid Crisis and Drug Enforcement Administration, "Counterfeit Prescription Pills Containing Fentanyl: A Global Threat," July 2016.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2404	07/2018	InSight Crime interviews with officials at Mexico federal police and Attorney General's Office, June, July 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2405	07/2018	InSight Crime interviews, San Diego and New Hampshire federal authorities, July 2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2406	07/17/2017	InSightCrime. Record Cocaine Production Colombia Fuels New Criminal Generation. Jeremy McDermott. July 17, 2017.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2407	08/2005	Sridhar Narayanan, et al., Temporal Differences in the Role of Marketing Communications in New Product Categories, Journal of Marketing Research, Vol. 42, pp. 278-290, August 2005				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2408	08/2008	The Neo Pathways Campaign: An Annotated Guide (Aug. 2008)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2409	08/2013	Muhuri, Pradip K. - "Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States" (Aug. 2013)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2410	08/2013	Substance Abuse and Mental Health Services Administration (SAMHSA). Muhiri P, Gfoerer J, Davies C. Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2411	08/2014	Emergency Medicine News. InFocus: Fentanyl-Laced Heroin A Deadly Combination. Roberts, James R. MD. April 2014 - Volume 36 - Issue 4 - p 13-15.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2412	08/2016	Christopher J. Ruhm, Taking the Measure of a Fatal Drug Epidemic, National Bureau of Economic Research Working Paper Series 22504, August 2016				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2413	08/2018	National Institute on Drug Abuse. Increased drug availability is associated with increased use and overdose. January 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2414	08/2018	Pham T, et al., Overview of Prescription Opioid Deaths in the Oklahoma State Medicaid Population, Medical Care, Volume 56, No. 8, pp. 727-735, August 2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2415	08/2018	Cohen J, El Khoury C, Milne C, Peters S. Rising Drug Costs Drives the Growth of Pharmacy Benefit Managers Exclusion Lists: Are Exclusion Decisions Value-Based? Health Services Research. Aug. 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2416	08/2018	National Institute on Drug Abuse. Overdose Death Rates. August 2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2417	09/2000	Andrea Coscelli, The Importance of Doctors' and Patients' Preferences in the Prescription Decision, The Journal of Industrial Economics, Vol. 48, No. 3, pp. 349-369, September 2000				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2418	09/2012	[Spreadsheet] Nucynta Roles - Staffing Scenarios	JAN-MS-00775849	JAN-MS-00775850		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2419	09/2018	FDA's Opioid Analgesic REMS Education Blueprint				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2420	09/2018	IBISWorld, "Pharmaceutical Manufacturing Industry in China: Industry Market Research Report," September 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2421	09/2018	FDA Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain, September 2018				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2422	10/1997	SUPP 9, Transdermal Fentanyl as Treatment for Chronic Low Back Pain, Richard Simpson and others				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2423	10/1997	Transdermal Fentanyl as Treatment for Chronic Low Back Pain, Richard Simpson and others				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2424	10/2012	Highlights of prescribing information for Nucynta	JAN-MS-01248173	JAN-MS-01248215		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2425	10/2017	InSight Crime interview, Appalachia health advocate, 18 June 2018. 60 US Drug Enforcement Administration, "2017 National Drug Threat Assessment," October 2017.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2426	10/2017	US Drug Enforcement Administration, "2017 National Drug Threat Assessment," October 2017.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2427	10/2018	US Drug Enforcement Administration, "2018 National Drug Threat Assessment," October 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2428	10/2018	US Drug Enforcement Administration, "2018 National Drug Threat Assessment," October 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2429	10/2008	NEO Pathways web conference brochure - Acute Pain Control Concerns & Consequences	JAN-MS-00471121	JAN-MS-00471122		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2430	10/14/2015	DURB Meeting Packet	OKAG-00006981	OKAG-00007133		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2431	11/2007	Letter re: Tapentadol Pain Leadership Steering Committee Meeting	JAN-MS-00475325	JAN-MS-00475325		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2432	11/2014	US-China Economic and Security Review Commission, "2014 Report to Congress," November 2014.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2433	12/2001	Pain: Current Understanding of Assessment, Management, and Treatments, National Pharmaceutical Council & Joint Commission on Accreditation of Healthcare Organizations, December 2001, available at <a href="https://www.npcnow.org/publication/paincurrent-understanding-assessment-management-and-treatments">https://www.npcnow.org/publication/paincurrent-understanding-assessment-management-and-treatments</a>				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2434	12/2002	[Word Doc] Major Changes in Market Place / Internal Events	JAN-MS-00305066	JAN-MS-00305066		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2435	12/2003	Ajay Kalra, et al., Understanding Responses to Contradictory Information About Products, Marketing Science, Vol. 30, No. 6, pp. 1098-1114, November-December 2011				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2436	12/2004	Natalie Mizik, et al., Are Physicians "Easy Marks"? Quantifying the Effects of Detailing and Sampling on New Prescriptions, Management Science, Vol. 50, No. 12, pp. 1704-1715, December 2004				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2437	12/2010	Nucynta Resource Guide	JAN-MS-00364042	JAN-MS-00364091		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2438	12/2010	Prescribe Responsibly Slide Deck	JAN-MS-00320643	JAN-MS-00320668		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2439	12/2011	Geoffrey F. Joyce, Ph.D., et al., Physician Prescribing Behavior and its Impact on Patient-Level Outcomes, The American Journal of Managed Care, Vol. 17, No. 12, pp. e462-e471, December 2011				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2440	12/2013	CNS Pain Team 2014 Call Plan Strategy	JAN-MS-01968557	JAN-MS-01968561		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2441	12/2014	Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) (Dec. 2014)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2442	12/2016	Centers for Disease Control and Prevention, "Drugs most frequently involved in drug overdose deaths. National Vital Statistics Reports - United States, 2010-2014," December 2016.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2443	12/2018	Centers for Disease Control and Prevention, "Provisional drug overdose death counts. National Center for Health Statistics," December 2018.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2444	2006/2007	Oklahoma Bureau of Narcotics: Diversion Report 2006-07	OKAG-00105678			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	



TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2445	2007-2011	Nowata, Osage, Rogers, and Washington Counties Unintentional Poisoning Data 2007-11	OSDH-00500253			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2446	2007-2011	Garvin, Grady, Murray, and Stephens Counties Unintentional Poisoning Data 2007-11	OSDH-00504581			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2447	03/2011	[Doc] Key talking points for speaker's being removed from the NUCYNTA bureau	JAN-MS-00826670	JAN-MS-00826670		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2448	2010	James, E. Wild et al., Article entitled, "Long-Term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain of Osteoarthritis Pain," World Institute of Pain, Vol. 10, Issue S, 2010, pp. 416-417				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2449	06/2007	[document] Medical Education Department Monthly Report	JAN-MS-00944920	JAN-MS-00944925		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2450	06/2008	"The Current State of Teenage Drug Abuse: Trend Toward Prescription Drugs."	JAN-MS-00945246	JAN-MS-00945263		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2451	06/2009	Duragesic Sixth Risk Management Plan Progress Report	JAN-MS-00151814	JAN-MS-00151814		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2452	06/2009	[Article] Clinical Courier, June 2009 - Optimizing Chronic Pain Management: Integrating Pharmacokinetics and Pharmacodynamics	JAN-MS-00393681	JAN-MS-00393692		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2453	06/2009	Nucynta pharmacy vis aid annotated	JAN-MS-04157172	JAN-MS-04157191		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2454	07/2012	[Newsletter] Nucynta Field Sales Memo	JAN-MS-01094765	JAN-MS-01094765		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2455	07/09/2002	DUR packet for 5/14/2002	OUCOP-00043603			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2456	08/2001	[Spreadsheet] Duragesic Publications Status	JAN-MS-00786470	JAN-MS-00786471		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2457	08/13/2002	DUR Packet for 7/9/2002 meeting	OUCOP-00039622			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2458	09/2009	[Email] PGHCC Integration of Training Material Review	JAN-MS-02000338	JAN-MS-02000350		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2459	09/2010	Nucynta dosing and administration guide	JAN-MS-04181502	JAN-MS-04181512		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2460	09/2012	Nucynta ohio medicaid card	JAN-MS-01076874	JAN-MS-01076875		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2461	09/2014	[Email] Signed work orders	JAN-MS-01971368	JAN-MS-01971372		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2462	9/17/2018	Colby Itkowitz, Article entitled, "The Health 202: Senators to vote on opioid package. But Big Hurdles Remain," The Washington Post, The Health 202				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2463		[Word Doc] Executive Summary - Duragesic Advisory Board Questions	JAN-MS-00385988			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2464	09/16/2005	JOM Standard Operating Procedure: Customer Service Order Processing of Controlled Substances	JAN-MS-03741177	JAN-MS-03741200		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2465	09/19/2005	JOM Customer Service Suspicious or Excessive Narcotic Orders.	JAN-MS-03741170	JAN-MS-03741176		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2466	11/17/2005	JOM Standard Operating Procedure: Customer JOM Standard Operating Procedure: Customer Service Schedule II-V Order Processing and Investigating Suspicious or Excessive Narcotics Orders	JAN-MS-03741201	JAN-MS-03741205		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2467	06/15/2005	Mercury Order Management User Requirements Specifications	JAN-MS-05442212	JAN-MS-05442253		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2468	07/13/2006	Order Management FRS Document	JAN-MS-05441988	JAN-MS-05442211		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2469	05/2015	2015 Suspicious Order Monitoring, JOM SOM Program	JAN-MS-02960646	JAN-MS-02960646		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2470		Controlled Substances Suspicious Order Monitoring Program Questionnaire	JAN-MS-03741206	JAN-MS-03741211		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2471		Attachment to email (JAN-MS-0312394), notes taken during DEA's 7/30/13 inspection at the Kentucky distribution center	JAN-MS-0312397	JAN-MS-03124005		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2472		Medical Records	OKAGSS_00110368			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2473		[Word] Common Objections and Appropriate Responses	JAN-MS-03007298			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2474		[Word] Common Objections and Appropriate Responses				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2475		[Word] NUCYNTA ER FAQ List				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2476		[Word] NUCYNTA Suggested Presentation	JAN-MS-00327255			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2477		[Approval Form] Nucynta Formulary Pricing Flashcard	JAN-MS-00464131			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2478		[Powerpoint] Welcome Tapentadol E-learning Project Kickoff	JAN-MS-00469584			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2479		[Word] SEVEN STUDIES OF TAPENTADOL IMMEDIATE RELEASE FOR ACUTE PAIN TO BE PRESENTED AT 2008 AMERICAN PAIN SOCIETY ANNUAL MEETING	JAN-MS-00928656			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2480		[Word] RESULTS OF PHASE 3 STUDY SHOW TAPENTADOL IR RELIEVES ACUTE PAIN AND OFFERS FAVORABLE GASTROINTESTINAL TOLERABILITY PROFILE	JAN-MS-00928658			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2481		[Word] JMA-51492: Second Draft Comments	JAN-MS-01011449			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2482		[Article] Analgesic Efficacy of Multiple-Doses of Tapentadol Immediate Release in Postsurgical Orthopedic (Bunionectomy) Pain: Results of a Phase II, Randomized, Double-blind, Placebo-Controlled Study	JAN-MS-01011479			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2483		[Powerpoint] Phase II	JAN-MS-01011585			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2484		[Email] abstracts	JAN-MS-01018739			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2485		[Email] Sales Training Review HCC Integration Team	JAN-MS-01124775			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2486		[Email] advise	JAN-MS-01124847			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2487		[Email] 24 Hour Launch workshop feedback: Needed Urgently	JAN-MS-01224841			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2488		[Email] Med/Reg/HCC Review: Tapentadol 24 Hour Launch Training Workshops (Due Jan 6th)	JAN-MS-01224843			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2489		[Email] For Review: Draft tapentadol (IR) approval press release	JAN-MS-01224875			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2490		[Email] PGHCC Integration of Training Material Review	JAN-MS-02000333			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2491		[Approval Form] duragesic.com Interim web site	JAN-MS-02008330			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2492		[Email] Suggested Presentation	JAN-MS-02202032			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2493		[PDF] Full Prescribing Information				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2494		[PDF] Full Prescribing Information				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2495		[Powerpoint] NUCYNTA PR Meeting - Welcome Weber Shandwick	JAN-MS-00018068			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2496		[Powerpoint] NUCYNTA PR Meeting - Welcome Weber Shandwick				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2497		Data and Analytics				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2498		Duragesic PADER Aug 1994-Jul 1996	JAN-MS-00291366	JAN-MS-00291366		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2499		Duragesic PADER Aug 1995-Jul 1996	JAN-MS-00291368	JAN-MS-00291368		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2500		Duragesic PADER Aug 1996-Jul 1997	JAN-MS-00291370	JAN-MS-00291370		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2501		Duragesic PADER Aug 1997-Jul 1998	JAN-MS-00291372	JAN-MS-00291372		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2502		Duragesic PADER Aug 1997-Jul 1998	JAN-MS-00291373	JAN-MS-00291373		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2503		Duragesic PADER Aug 1998-Jul 1999	JAN-MS-00291375	JAN-MS-00291375		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2504		Duragesic PADER Aug 1998-Jul 1999	JAN-MS-00291376	JAN-MS-00291376		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2505		Duragesic PADER Aug 1998-Jul 1999	JAN-MS-00291377	JAN-MS-00291377		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2506		Duragesic PADER Aug 1998-Jul 1999	JAN-MS-00291378	JAN-MS-00291378		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2507		Duragesic PADER Aug 1998-Jul 1999	JAN-MS-00291379	JAN-MS-00291379		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2508		Duragesic PADER Aug 1998-Jul 1999	JAN-MS-00291380	JAN-MS-00291380		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2509		Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291382	JAN-MS-00291382		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2510		Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291383	JAN-MS-00291383		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2511		Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291384	JAN-MS-00291384		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2512		Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291385	JAN-MS-00291385		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2513		Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291386	JAN-MS-00291386		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2514		Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291387	JAN-MS-00291387		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2515		Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291388	JAN-MS-00291388		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2516		Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291389	JAN-MS-00291389		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2517		Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291390	JAN-MS-00291390		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2518		Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291391	JAN-MS-00291391		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2519		Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291392	JAN-MS-00291392		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2520		Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291393	JAN-MS-00291393		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2521		Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291394	JAN-MS-00291394		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2522		Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291395	JAN-MS-00291395		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2523		Duragesic PADER Aug 2000-Jul 2001	JAN-MS-00291397	JAN-MS-00291397		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2524		Duragesic PADER Aug 2000-Jul 2001	JAN-MS-00291398	JAN-MS-00291398		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2525		Duragesic PADER Aug 2000-Jul 2001	JAN-MS-00291399	JAN-MS-00291399		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2526		Duragesic PADER Aug 2000-Jul 2001	JAN-MS-00291400	JAN-MS-00291400		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2527		Duragesic PADER Aug 2000-Jul 2001	JAN-MS-00291401	JAN-MS-00291401		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2528		Duragesic PADER Aug 2000-Jul 2001	JAN-MS-00291402	JAN-MS-00291402		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2529		Duragesic PADER Aug 2000-Jul 2001	JAN-MS-00291403	JAN-MS-00291403		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2530		Duragesic PADER Aug 2001-Apr 2002	JAN-MS-00291405	JAN-MS-00291405		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2531		Duragesic PADER Aug 2001-Apr 2002	JAN-MS-00291406	JAN-MS-00291406		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2532		Duragesic PADER Aug 2001-Apr 2002	JAN-MS-00291407	JAN-MS-00291407		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2533		Duragesic PADER Aug 2001-Apr 2002	JAN-MS-00291408	JAN-MS-00291408		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2534		Duragesic PADER Aug 2001-Apr 2002	JAN-MS-00291409	JAN-MS-00291409		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2535		Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213707	JAN-MS-00213707		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2536		Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213708	JAN-MS-00213708		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2537		Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213709	JAN-MS-00213709		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2538		Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213710	JAN-MS-00213710		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2539		Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213711	JAN-MS-00213711		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2540		Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213712	JAN-MS-00213712		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2541		Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213713	JAN-MS-00213713		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2542		Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213715	JAN-MS-00213715		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2543		Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213716	JAN-MS-00213716		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2544		Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213717	JAN-MS-00213717		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2545		Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213718	JAN-MS-00213718		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2546		Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213719	JAN-MS-00213719		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2547		Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213720	JAN-MS-00213720		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2548		Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213721	JAN-MS-00213721		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2549		Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213722	JAN-MS-00213722		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2550		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213723	JAN-MS-00213723		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2551		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213724	JAN-MS-00213724		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2552		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213725	JAN-MS-00213725		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2553		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213726	JAN-MS-00213726		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2554		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213727	JAN-MS-00213727		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2555		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213728	JAN-MS-00213728		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2556		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213729	JAN-MS-00213729		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2557		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213730	JAN-MS-00213730		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2558		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213731	JAN-MS-00213731		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2559		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213732	JAN-MS-00213732		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2560		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213734	JAN-MS-00213734		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2561		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213735	JAN-MS-00213735		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2562		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213736	JAN-MS-00213736		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2563		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213737	JAN-MS-00213737		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2564		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213738	JAN-MS-00213738		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2565		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213739	JAN-MS-00213739		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2566		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213740	JAN-MS-00213740		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2567		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213741	JAN-MS-00213741		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2568		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213742	JAN-MS-00213742		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2569		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213743	JAN-MS-00213743		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	



TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2570		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213744	JAN-MS-00213744		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2571		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213745	JAN-MS-00213745		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2572		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213746	JAN-MS-00213746		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2573		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213747	JAN-MS-00213747		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2574		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213748	JAN-MS-00213748		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2575		Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213749	JAN-MS-00213749		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2576		Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291410	JAN-MS-00291410		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2577		Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291411	JAN-MS-00291411		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2578		Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291412	JAN-MS-00291412		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2579		Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291413	JAN-MS-00291413		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2580		Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291414	JAN-MS-00291414		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2581		Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291415	JAN-MS-00291415		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2582		Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291416	JAN-MS-00291416		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2583		Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291417	JAN-MS-00291417		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2584		Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291418	JAN-MS-00291418		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2585		Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291419	JAN-MS-00291419		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2586		Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291421	JAN-MS-00291421		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2587		Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291422	JAN-MS-00291422		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2588		Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291423	JAN-MS-00291423		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2589		Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291424	JAN-MS-00291424		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2590		Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291425	JAN-MS-00291425		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2591		Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291426	JAN-MS-00291426		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2592		Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291427	JAN-MS-00291427		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2593		Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291428	JAN-MS-00291428		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2594		Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291429	JAN-MS-00291429		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2595		Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291430	JAN-MS-00291430		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2596		Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291431	JAN-MS-00291431		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2597		Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291432	JAN-MS-00291432		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2598		Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291433	JAN-MS-00291433		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2599		Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291434	JAN-MS-00291434		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2600		Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291435	JAN-MS-00291435		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2601		Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291436	JAN-MS-00291436		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2602		Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291437	JAN-MS-00291437		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2603		Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291438	JAN-MS-00291438		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2604		Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291439	JAN-MS-00291439		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2605		Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291440	JAN-MS-00291440		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2606		Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291441	JAN-MS-00291441		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2607		Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291442	JAN-MS-00291442		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2608		Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291443	JAN-MS-00291443		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2609		Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291444	JAN-MS-00291444		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2610		Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291445	JAN-MS-00291445		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2611		Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291446	JAN-MS-00291446		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2612		Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291447	JAN-MS-00291447		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2613		Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291448	JAN-MS-00291448		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2614		Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291449	JAN-MS-00291449		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2615		Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291450	JAN-MS-00291450		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2616		Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291451	JAN-MS-00291451		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2617		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213785	JAN-MS-00213785		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2618		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213787	JAN-MS-00213787		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2619		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213788	JAN-MS-00213788		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2620		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213789	JAN-MS-00213789		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2621		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213790	JAN-MS-00213790		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2622		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213791	JAN-MS-00213791		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2623		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213792	JAN-MS-00213792		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2624		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213793	JAN-MS-00213793		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2625		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213794	JAN-MS-00213794		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2626		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213796	JAN-MS-00213796		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2627		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213797	JAN-MS-00213797		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2628		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213798	JAN-MS-00213798		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2629		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213799	JAN-MS-00213799		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2630		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213800	JAN-MS-00213800		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2631		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213801	JAN-MS-00213801		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2632		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213802	JAN-MS-00213802		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2633		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213803	JAN-MS-00213803		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2634		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213804	JAN-MS-00213804		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2635		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213805	JAN-MS-00213805		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2636		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213806	JAN-MS-00213806		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2637		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213807	JAN-MS-00213807		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2638		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213808	JAN-MS-00213808		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2639		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213809	JAN-MS-00213809		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2640		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213810	JAN-MS-00213810		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2641		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213811	JAN-MS-00213811		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2642		Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213812	JAN-MS-00213812		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2643		Assessment of the Abuse of Transdermal Fentanyl, John J. Coleman	JAN-MS-00789392	JAN-MS-00789402		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2644		Extended-Release and Long-Acting Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS)	JAN-MS-00935481	JAN-MS-00935534		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2645		APF: Pain Resource Guide, pp. 1,7 (Tab 2 of Ex. 21 from 1/9/19 depo)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2646		APF: Pain Notebook, p. 6 (Tab 3 of Ex. 21 from 1/9/19 depo)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2647		APS Glossary of Pain Terms (Tab 4 of Ex. 21 from 1/9/19 depo)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2648		Currents Pain Monograph (Tab 5 of Ex. 21 from 1/9/19 depo)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2649		Treating Doctors as Drug Dealers; The DEA's War on Prescription Painkillers; Ronald T. Libby (Tab 6 of Ex. 21 from 1/9/19 depo)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2650		NEJM: Opioid Therapy for Chronic Pain Article (Tab 7 of Ex. 21 from 1/9/19 depo)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2651		Portenoy RK, Payne R, Passik SK, Lowinson JH, Ruz P, Millman RB, Langrod JG. Substance Abuse: A Comprehensive Textbook. 4th ed. Philadelphia: Lippincott, William & Wilkens; 2004. Acute and Chronic Pain (Tab 8 of Ex. 21 from 1/9/19 depo)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2652		DUR 1, 1987 Duragesic IND-NDA Safety Summary	JAN-MS-00213627	JAN-MS-00213627		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2653		DUR 2, 1990 Duragesic Safety Update	JAN-MS-00213588	JAN-MS-00213588		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2654		DUR 3, 1990-1991 Duragesic Annual Report	JAN-MS-00213680	JAN-MS-00213680		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2655		DUR 4, 1991-1992 Duragesic Annual Report	JAN-MS-00213683	JAN-MS-00213683		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2656		DUR 5, 1992-1993 Duragesic Annual Report	JAN-MS-03087739	JAN-MS-03087739		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2657		DUR 6, 1993-1994 Duragesic Annual Report	JAN-MS-00213688	JAN-MS-00213688		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2658		DUR 7, 1994-1995 Duragesic Annual Report	JAN-MS-00213692	JAN-MS-00213692		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2659		DUR 8, 1995-1996 Duragesic Annual Report	JAN-MS-00213695	JAN-MS-00213695		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2660		DUR 9, 1996-1997 Duragesic Annual Report	JAN-MS-00213699	JAN-MS-00213699		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2661		DUR 10, 1997-1998 Duragesic Annual Report	JAN-MS-00213702	JAN-MS-00213702		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2662		DUR 11, 1998-1999 Duragesic Annual Report	JAN-MS-00213705	JAN-MS-00213705		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2663		DUR 12, 1999-2000 Duragesic Annual Report	JAN-MS-03087746	JAN-MS-03087746		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2664		DUR 13, 2000-2001 Duragesic Annual Report	JAN-MS-03087748	JAN-MS-03087748		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2665		DUR 14, 2001-2002 Duragesic Annual Report	JAN-MS-03087753	JAN-MS-03087753		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2666		DUR 15, 2002-2003 Duragesic PSUR Studies	JAN-MS-00213714	JAN-MS-00213714		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2667		DUR 16, 2003-2004 Duragesic PSUR Studies	JAN-MS-00213773	JAN-MS-00213773		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2668		DUR 17, 2004-2005 Duragesic PSUR Studies	JAN-MS-00291420	JAN-MS-00291420		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2669		DUR 18, 2005-2006 Duragesic PSUR Studies	JAN-MS-00291442	JAN-MS-00291442		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2670		DUR 19, 2006-2007 Duragesic PSUR Studies	JAN-MS-00213795	JAN-MS-00213795		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2671		DUR 20, 2007-2008 Duragesic PSUR	JAN-MS-00132853	JAN-MS-00132853		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2672		DUR 21, 2008-2009 Duragesic PSUR	JAN-MS-00151818	JAN-MS-00151818		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2673		DUR 22, 2009-2010 Duragesic PSUR	JAN-MS-0165630	JAN-MS-0165630		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2674		DUR 23, 2010-2011 Duragesic PSUR	JAN-MS-00185387	JAN-MS-00185387		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2675		DUR 24, 2011-2012 Duragesic PSUR	JAN-MS-00198542	JAN-MS-00198542		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2676		DUR 25, 2012-2013 Duragesic PSUR	JAN-MS-00207095	JAN-MS-00207095		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2677		DUR 26, 2013-2014 Duragesic PSUR Studies	JAN-MS-00213464	JAN-MS-00213464		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2678		DUR 27, 2014-2015 Duragesic PSUR Studies	JAN-MS-00291192	JAN-MS-00291192		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2679		DUR 28, 2015-2016 Duragesic PSUR Studies	JAN-MS-00291230	JAN-MS-00291230		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2680		OUR 29, 2016-2017 Duragesic PSUR Studies	JAN-MS-00291322	JAN-MS-00291322		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2681		IR 1, 2007 Nucynta IR IND-NDA Clinical Summary	JAN-MS-00230459	JAN-MS-00230459		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2682		IR 2, 2010 Nucynta IR Annual Report Clinical Summary	JAN-MS-00235144	JAN-MS-00235144		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2683		IR 3, 2010 Nucynta IR Annual Report Other PMR Studies	JAN-MS-00235142	JAN-MS-00235142		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2684		IR 4, 2010 Nucynta IR Annual Report PMR Commitments	JAN-MS-00235143	JAN-MS-00235143		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2685		IR 5, 2011 Nucynta IR Annual Report Other PMR Studies	JAN-MS-00235204	JAN-MS-00235204		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2686		IR 6, 2011 Nucynta Annual Report Clinical Summary	JAN-MS-00235206	JAN-MS-00235206		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2687		IR 7, 2011 Nucynta IR Annual Report PMR Commitments	JAN-MS-00235205	JAN-MS-00235205		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2688		IR 8, 2011 Nucynta IR Annual Report Significant New Info	JAN-MS-00235210	JAN-MS-00235210		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2689		IR 9, 2012 Nucynta IR Annual Report Clinical Summary	JAN-MS-00235266	JAN-MS-00235266		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2690		IR 10, 2012 Nucynta IR Annual Report Other PMR Studies	JAN-MS-00235264	JAN-MS-00235264		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2691		IR 11, 2012 Nucynta IR Annual Report Other Significant Info	JAN-MS-00235270	JAN-MS-00235270		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2692		IR 12, 2012 Nucynta IR Annual Report PMR Commitments	JAN-MS-00235265	JAN-MS-00235265		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2693		IR 13, 2013 Nucynta IR Annual Report Clinical Summary	JAN-MS-00235292	JAN-MS-00235292		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2694		IR 14, 2013 Nucynta IR Annual Report Other Significant Information	JAN-MS-00235296	JAN-MS-00235296		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2695		IR 15, 2013 Nucynta IR Annual Report PMR Commitments	JAN-MS-00235291	JAN-MS-00235291		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	



TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2696		IR 16, 2014 Nucynta IR Annual PMR Commitments	JAN-MS-00235314	JAN-MS-00235314		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2697		IR 17, 2014 Nucynta IR Annual Report Clinical Summary	JAN-MS-00235315	JAN-MS-00235315		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2698		IR 18, 2014 Nucynta IR Annual Report Other Significant Information	JAN-MS-00235318	JAN-MS-00235318		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2699		IR 19, 2015 Nucynta IR Annual Report Clinical Summary	JAN-MS-00235335	JAN-MS-00235335		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2700		IR 20, 2015 Nucynta IR Annual Report Other Significant Info	JAN-MS-00235340	JAN-MS-00235340		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2701		IR 21, 2015 Nucynta IR Annual Report PMR Commitments	JAN-MS-00235334	JAN-MS-00235334		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2702		ER 1, 2009 Nucynta ER IND-NDA Clinical Summary	JAN-MS-00214445	JAN-MS-00214445		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2703		ER 2, 2012 Nucynta ER Annual Report Clinical Summary	JAN-MS-00228477	JAN-MS-00228477		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2704		ER 3, 2012 Nucynta ER Annual Report Other PMR Studies	JAN-MS-00228474	JAN-MS-00228474		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2705		ER 4, 2012 Nucynta ER Annual Report Other Significant Info	JAN-MS-00228481	JAN-MS-00228481		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2706		ER 5, 2012 Nucynta ER Annual Report PMR Commitments	JAN-MS-00228476	JAN-MS-00228476		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2707		ER 6, 2013 Nucynta ER Annual Report Clinical Summary	JAN-MS-00228539	JAN-MS-00228539		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2708		ER 7, 2013 Nucynta ER Annual Report Other PMR Studies	JAN-MS-00228537	JAN-MS-00228537		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2709		ER 8, 2013 Nucynta ER Annual Report PMR Commitments	JAN-MS-00228538	JAN-MS-00228538		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2710		ER 9, 2014 Nucynta ER Annual Report Other Significant Info	JAN-MS-00228622	JAN-MS-00228622		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2711		ER 10, 2014 Nucynta ER NDA 2014 PMR Commitments	JAN-MS-00228619	JAN-MS-00228619		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2712		ER 11, 2014 Nucynta ER NDA Annual Report Clinical Summary	JAN-MS-00228623	JAN-MS-00228623		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2713		SUPP 1, Nucynta ER Tamper Resistant Formulation Summary	JAN-MS-00214472	JAN-MS-00214472		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2714		SUPP 2, Nucynta ER Intranasal Abuse Report	JAN-MS-00214470	JAN-MS-00214470		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2715		SUPP 3, Nucynta ER Intravenous Abuse Report	JAN-MS-00214471	JAN-MS-00214471		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2716		The 2012 Johnson Medal for Research and Development Nomination -- Full Application: Nucynta/Nucynta ER	JAN-MS-02604007	JAN-MS-02604012		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2717		RADARS Report	JAN-MS-00483327	JAN-MS-00483328		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2718		NIDA: Pain Assessment and Documentation Tool (PADT)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2719		SoonerCare Oklahoma Health Care Authority Pain Management Program				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2720		Letter approving ER/LA REMS with REMS attached	JAN-MS-02099676	JAN-MS-02099723		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2721		Prescribe Responsibly home page				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2722		Rationale for the Development, Therapeutic Use, and Clinical Program for Transdermal Therapeutic System (Fentanyl)	JAN-MS-02908137	JAN-MS-02908151		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2723		FDA-Required REMS Program for Serious Drugs Prescriber Letter	JAN-MS-01047964	JAN-MS-01047965		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2724		Prescribe Responsibly full website				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2725		Smart Moves, Smart Choices 2008 Rollout Plan presentation	JAN-MS-00275603	JAN-MS-00275603		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2726		Overview of Smart Moves, Smart Choices presentation	JAN-MS-00343143	JAN-MS-00343143		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS [Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them]
J2727		Smart Moves, Smart Choices About page				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2728		Smart Moves, Smart Choices Elementary Smart Start Tools webpage				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2729		Smart Moves, Smart Choices Tool Kit for Middle and High Schools webpage				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2730		Smart Moves, Smart Choices Choices video webpage				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2731		Start Smart Program Overview	JAN-MS-00428464	JAN-MS-00428466		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2732		Smart Moves, Smart Choices Animated Video Discussion Guide	JAN-MS-00428467	JAN-MS-00428473		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2733		Nurse.com Confronting the Opioid Epidemic Webpage				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2734		About Nurse.com Webpage				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2735		Nurse.com Opioid Use Course Description				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2736		Nurse.com Health Literacy Course Description				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2737		Nurse.com Patient Counseling Course Description				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2738		Nurse.com Meeting the Challenge Course Description				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2739		Nurse.com Responsible Opioid Prescribing Course Description				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2740		Nurse.com Prescription Drug Abuse Course Description				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2741		Nurse.com Pain Management Course Description				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2742		Nurse.com Chronic Pain Course Description				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2743		Nurse.com Effective Pain Management Course Description				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2744		Nurse.com Substance Abuse Course Description				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2745		Nurse.com Medical Non-Adherence Course Description				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2746		Nurse.com Knocking Out Course Description				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2747		Nurse.com Recognizing Course Description				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2748		Nurse.com Evidence-Based Course Description				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2749		Nurse.com Motivational Course Description				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2750		About BabyCenter Webpage				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2751		BabyCenter.com Editorial and Advertising Policy Webpage				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2752		BabyCenter.com Advisory Board webpage				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J2753		BabyCenter.com What Are Opioids Webpage				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2754		BabyCenter.com Which Medicines Contain Opioids Webpage				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2755		BabyCenter.com Is It Safe to Take Opioids During Pregnancy Webpage				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2756		BabyCenter.com Is It Safe to Take Opioids While Breastfeeding Webpage				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2757		BabyCenter.com Is It Safe to Take Opioids During Labor Webpage				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2758		BabyCenter.com What Is My Risk Webpage				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2759		BabyCenter.com How Can I Minimize my Risk Webpage				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2760		BabyCenter.com What Are The Signs Webpage				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2761		Approved Risk Evaluation and Mitigation Strategies Opioid Analgesic REMS				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2762		Duragesic Label (8-1990)	JAN-MS-00238727	JAN-MS-00238737		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2763		Duragesic Label (3-1993, 8-1993)	JAN-OK-00144086	JAN-OK-00144097		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2764		Duragesic Label (8-1993, 1-1994)	JAN-OK-00144123	JAN-OK-00144134		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2765		Duragesic Label (1-1994, 6-1994)	JAN-OK-00144098	JAN-OK-00144109		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J2766		Duragesic Label (Rev4-1998, 11-1999)	JAN-OK-00144110	JAN-OK-00144117		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	